TWI405536B - 用於防止微生物附著之非濾出型界面活性膜組成物 - Google Patents
用於防止微生物附著之非濾出型界面活性膜組成物 Download PDFInfo
- Publication number
- TWI405536B TWI405536B TW096101746A TW96101746A TWI405536B TW I405536 B TWI405536 B TW I405536B TW 096101746 A TW096101746 A TW 096101746A TW 96101746 A TW96101746 A TW 96101746A TW I405536 B TWI405536 B TW I405536B
- Authority
- TW
- Taiwan
- Prior art keywords
- meth
- group
- coating composition
- acrylamide
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- 230000000813 microbial effect Effects 0.000 title claims description 46
- 238000002386 leaching Methods 0.000 title abstract description 35
- 230000002265 prevention Effects 0.000 title description 3
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 99
- 238000000576 coating method Methods 0.000 claims abstract description 85
- 239000011248 coating agent Substances 0.000 claims abstract description 77
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims abstract description 41
- 244000005700 microbiome Species 0.000 claims abstract description 39
- 229920000642 polymer Polymers 0.000 claims abstract description 35
- 125000000524 functional group Chemical group 0.000 claims abstract description 32
- 239000000126 substance Substances 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- 150000001412 amines Chemical class 0.000 claims abstract description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
- -1 vinyl pyridinium halide Chemical class 0.000 claims description 98
- 239000008199 coating composition Substances 0.000 claims description 68
- 239000004814 polyurethane Substances 0.000 claims description 59
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 57
- 229920002635 polyurethane Polymers 0.000 claims description 57
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 51
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 34
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 32
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 27
- 229920001577 copolymer Polymers 0.000 claims description 26
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 24
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 239000003431 cross linking reagent Substances 0.000 claims description 18
- 239000012948 isocyanate Substances 0.000 claims description 16
- 150000002513 isocyanates Chemical class 0.000 claims description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 229920005862 polyol Polymers 0.000 claims description 15
- 239000003093 cationic surfactant Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 11
- 230000002147 killing effect Effects 0.000 claims description 11
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 10
- 210000002421 cell wall Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- 229920002401 polyacrylamide Polymers 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000001299 aldehydes Chemical class 0.000 claims description 8
- 229960003237 betaine Drugs 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 239000003139 biocide Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 230000008020 evaporation Effects 0.000 claims description 7
- 150000002430 hydrocarbons Chemical group 0.000 claims description 7
- 229920001480 hydrophilic copolymer Polymers 0.000 claims description 7
- 239000000178 monomer Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 7
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 claims description 6
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- CBECDWUDYQOTSW-UHFFFAOYSA-N 2-ethylbut-3-enal Chemical compound CCC(C=C)C=O CBECDWUDYQOTSW-UHFFFAOYSA-N 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 5
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 108010076119 Caseins Proteins 0.000 claims description 5
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 101100462438 Mus musculus Otulin gene Proteins 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021240 caseins Nutrition 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- JTHNLKXLWOXOQK-UHFFFAOYSA-N n-propyl vinyl ketone Natural products CCCC(=O)C=C JTHNLKXLWOXOQK-UHFFFAOYSA-N 0.000 claims description 5
- 229920001220 nitrocellulos Polymers 0.000 claims description 5
- 229920000768 polyamine Polymers 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 5
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 4
- AFYJIPGNQDXCDQ-UHFFFAOYSA-N C(C)CCCCCCCCNC=C Chemical compound C(C)CCCCCCCCNC=C AFYJIPGNQDXCDQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 239000000417 fungicide Substances 0.000 claims description 4
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 229920000877 Melamine resin Polymers 0.000 claims description 3
- 230000023555 blood coagulation Effects 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 3
- 230000000855 fungicidal effect Effects 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 3
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000000934 spermatocidal agent Substances 0.000 claims 1
- 239000003206 sterilizing agent Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 abstract description 57
- 238000000034 method Methods 0.000 abstract description 42
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 230000007774 longterm Effects 0.000 abstract description 11
- 150000003573 thiols Chemical class 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000009257 reactivity Effects 0.000 abstract description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 52
- 239000000853 adhesive Substances 0.000 description 31
- 230000001070 adhesive effect Effects 0.000 description 31
- 229920001228 polyisocyanate Polymers 0.000 description 28
- 239000005056 polyisocyanate Substances 0.000 description 28
- 238000012360 testing method Methods 0.000 description 23
- 241000588724 Escherichia coli Species 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 239000011521 glass Substances 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 13
- 229920006264 polyurethane film Polymers 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229920003023 plastic Polymers 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 238000005464 sample preparation method Methods 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 229940116333 ethyl lactate Drugs 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 6
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 239000004800 polyvinyl chloride Substances 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 208000012868 Overgrowth Diseases 0.000 description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 229920002118 antimicrobial polymer Polymers 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000004744 fabric Substances 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000004381 surface treatment Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000004721 Polyphenylene oxide Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229910001092 metal group alloy Inorganic materials 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 230000000399 orthopedic effect Effects 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QIKIJFUVHGOQOK-UHFFFAOYSA-M (3-chloro-2-hydroxypropyl)-dimethyl-octadecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC(O)CCl QIKIJFUVHGOQOK-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000003973 paint Substances 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 2
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000010065 bacterial adhesion Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001688 coating polymer Polymers 0.000 description 2
- 239000004567 concrete Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000007731 hot pressing Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007974 melamines Chemical class 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 150000002924 oxiranes Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 229960003656 ricinoleic acid Drugs 0.000 description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- CSPHGSFZFWKVDL-UHFFFAOYSA-M (3-chloro-2-hydroxypropyl)-trimethylazanium;chloride Chemical class [Cl-].C[N+](C)(C)CC(O)CCl CSPHGSFZFWKVDL-UHFFFAOYSA-M 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- UEFCKYIRXORTFI-UHFFFAOYSA-N 1,2-thiazolidin-3-one Chemical compound O=C1CCSN1 UEFCKYIRXORTFI-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- OWRCNXZUPFZXOS-UHFFFAOYSA-N 1,3-diphenylguanidine Chemical compound C=1C=CC=CC=1NC(=N)NC1=CC=CC=C1 OWRCNXZUPFZXOS-UHFFFAOYSA-N 0.000 description 1
- PXMNMQRDXWABCY-UHFFFAOYSA-N 1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol Chemical compound C1=NC=NN1CC(O)(C(C)(C)C)CCC1=CC=C(Cl)C=C1 PXMNMQRDXWABCY-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- VGVRPFIJEJYOFN-UHFFFAOYSA-N 2,3,4,6-tetrachlorophenol Chemical class OC1=C(Cl)C=C(Cl)C(Cl)=C1Cl VGVRPFIJEJYOFN-UHFFFAOYSA-N 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- MMEDJBFVJUFIDD-UHFFFAOYSA-N 2-[2-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC=C1CC(O)=O MMEDJBFVJUFIDD-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- MVZBYZAIKPPGSW-UHFFFAOYSA-N 4-bromobutan-1-amine Chemical compound NCCCCBr MVZBYZAIKPPGSW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000005822 Propiconazole Substances 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000005839 Tebuconazole Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 229960000870 betamethasone benzoate Drugs 0.000 description 1
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 159000000006 cesium salts Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 description 1
- 229960001357 clocortolone pivalate Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940057004 coal tar extract Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 238000007590 electrostatic spraying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940005667 ethyl salicylate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012765 fibrous filler Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 239000005003 food packaging material Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940029355 iodipamide Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940029378 iothalamate Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 238000007761 roller coating Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003678 scratch resistant effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/17—Amines; Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/48—Surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/0427—Coating with only one layer of a composition containing a polymer binder
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/046—Forming abrasion-resistant coatings; Forming surface-hardening coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/054—Forming anti-misting or drip-proofing coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/056—Forming hydrophilic coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
- C08L75/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
- C09D175/04—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/452—Lubricants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2290/00—Compositions for creating anti-fogging
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
- C08J2375/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2475/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Wood Science & Technology (AREA)
- Manufacturing & Machinery (AREA)
- Paints Or Removers (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
本發明係有關於形成界面活性、非濾出型抗微生物膜之組成物及其施加至表面以使該表面具有非濾出型抗微生物性質之方法。本發明該等組成物可形成具有長期抗微生物效力之持久塗層,且不會形成抑制區。根據本發明之組成物亦係有關於具有可減少血液凝固之性質的持久性非濾出型塗料。
在水存在及合適溫度條件下,微生物可以以很快的速度生長及繁殖。據估計於合適溫度及濕度條件下,微生物(例如細菌)之菌群每20分鐘可增加一倍。藉各種方法以防止微生物之危害量為我們日常生活非做不可的事。藉以水清洗或以肥皂及水洗掉而預防感染為常用以減少皮膚上之微生物含量的方法。亦以多種濃度及在多種應用上使用具有可殺死微生物之各種水溶度及生體可用率的許多抗微生物藥劑或物質。此等藥劑或物質之實例包括殺生物劑、防腐劑、抗微生物劑及抗生素。此種藥劑之作用方式可不同。
一控制微生物生長及增殖之方法為提供控制量之抗微生物藥劑並使其恆定地有效殺死該藥劑附近之微生物。該抗微生物藥劑可以以促証殺死微生物之特殊釋放機制包埋或包封在特定介質內以保護下面的基質或可逐漸釋放入需要長時間防止微生物侵襲之環境內。據生物試驗方法的觀點,該等抗微生物劑可以在其所包埋或包封之介質周圍形成殺滅區或區域,該殺滅區或區域可根據該抗微生物劑之濃度及效力強度而不同。可恆定地濾出特定量以提供微生物不能存活之區域。該溶析量必需高於最低抑制濃度(MIC)。通常使用約95%之殺滅效果以確定抗微生物劑之MIC值。通常測定MIC值以比較不同抗生物劑之效力強度。所形成之無微生物生長的區域稱為“抑制區”。
用以描述抗微生物機能之其它名詞包括制菌性、制真菌性及制生物性。在許多情況下,該等定義係與該等名詞,殺菌性、殺真菌性及殺生物性,相同。然而,該等殺害性(-cidal)名詞通常代表可完全消滅或去除,而該抑制性(-static)名詞係代表可以使該數量剛好維持平衡狀態。因此抑制性係指可殺滅數量實質上等於新發育微生物之殺生物的藥劑。據如上述MIC值之觀點,該值可以是約50%殺滅強度。然而,作為制菌性及殺菌性成份之活性化學化合物的作用模式仍被視為相同。美國專利第2,510,428號揭示2,3二苯基吲哚之制菌性及殺菌性濃度範圍自0.1 ppm至5%,其係取決於抗微生物效力之濃度梯度。英國專利GB 871228揭示藉含苯乙烯/丙烯腈之氯酚的擠製法而形成之制生物性塑膠。英國專利871228說明重複清洗後所使用多年後仍可維持抗微生物效力。該等氯酚可遷移至該塑膠之表面以提供制生物活性。然而,其可在該塑膠表面之周圍形成抑制區,且經過一段時間後,該等氯酚會逐漸耗盡。
每當表面有微生物可自由接近的機會時,該等微生物可附著於此等表面,所以這些表面會發生微生物污染。因此,就許多應用而言,最好防止此等微生物附著於表面。用達成此目標之幾種方法業經建議。其中一種方法為將該表面恆定地加熱至高於該等微生物之存活溫度以上之溫度。其未必實用或合乎經濟。已建議之確認抗細菌表面性質的其它方法包括使抗微生物藥劑、消毒劑或抗生素固定在相關表面(例如纖維質表面、合成織物表面或醫用裝置表面)上以減少細菌附著並接著可防止細菌感染。該等表面係藉將抗微生物化合物截留或包埋在表面塗料中而製成。這些表面包括濾出機制及產生抑制區。亦已建議活性成份之化學性鍵結(靜電性鍵結、離子鍵結或共價鍵結)以預防在相關表面上之微生物附著。然而,在許多情況下,例如就五氯酚與聚合物質質之共價鍵結而言,毒物學的副作為令人擔憂的問題。在大多數其它情況下,由於不同分子實體之合成,該抗微生物效力會損失。
已建議之其它使活性成份固定化以得到非濾出型抗微生物性質之嘗試包括離子四級銨化合物鍵結機制,諸如在美國專利第4,229,838號、第4,613,517號、第4,678,660號、第4,713,402號及第5,451,424號中所述之抗微生物界面活性聚合物。然而,該離子鍵結可重大地限制此等表面有效性之壽命。在水性環境內經過相當短的時間,該等離子鍵結抗微生物分子團可被洗掉。界面活性聚合物之另外實例係揭示在以下專利中:美國專利第5,783,502號、第6,251,967號、第6,497,868號,以及美國專利公開申請案第2002/0051754號、第2002/0177828號、第2003/0175503號與第2003/117579號。雖然這些參考文獻詳述活性抗微生物藥劑之減少濾出,但是亦揭示可以使非濾出型分子團得到長期效力之共價鍵結機制或親水表面性質。此外,有其它參考文獻建議使用非濾出型活性抗微生物藥劑以提供抗微生物表面,但是其包括可提供抑制區之“非濾出型”的定義。
使用具有特定官能基之長鏈抗微生物劑的抗微生物表面亦業經建議。與使抗微生物劑在溶液中有效(其中微生物係在自由流動之水性或低流動性但是潮濕的環境中經相當少的殺生物分子實體侵襲)之方法比較,據建議該等長鏈抗微生物劑係藉不同作用方式而提供殺滅表面。所建議之作用模式包括該等長鏈分子團穿透微生物細胞內。該經穿刺之細胞死亡,且該錨形長鏈隨時可穿插下一個細胞。然而,使用長鏈抗微生物劑之該等先前技藝之方法具有以下缺點:由於與該表面不充份鍵結或微生物死體積聚在該表面上,經過一段時間後其效力明顯降低,且由於該等穿透分子團之濾出或分離而形成抑制區。
本發明之一目標為提供可形成具有長期抗微生物效力且不會形成抑制區及無上述缺點之持久塗料的組成物。
本發明另一目標為提供形成界面活性抗微生物膜之組成物,其包括一旦基質乾燥或固化時可以與該聚合物基質化學性鍵結以得到具有長期抗微生物效力之非濾出型表面的長鏈分子。
本發明另一目標為提供根據上述目標之塗料,其係為可良好地附著於基質之選擇性親水及潤滑性有機塗料,且其適於與血液接觸之應用,此等塗料不會使血液凝固在該經塗覆之表面上。
本發明為非濾出型抗微生物塗料組成物,一旦乾燥且其載體溶劑蒸發時,該組成物可提供能預防微生物(例如細菌)附著之表面。本發明亦包括製備並施加本發明該組成物之方法。一般相信其作用模式為微生物細胞壁穿刺機制,且由於濾出,所以不會形成抑制區。具有反應性基團之聚合物基質係與特定抗微生物分子之反應性基團對應物反應以形成新化學性,例如共價鍵結之非濾出型聚合物基質,且基於濾出而將該原有抗微生物效果轉化成不會濾出之抗微生物效果。
所製成表面之穿刺分子團經固定化且不會濾出。該等穿刺分子團較佳共價鍵結,因此其不會容易地進滿水解,所以可釋放並洗掉該等穿刺分子團。就MIC而言,較佳未形成抑制區,且該MIC值遠低於50%值,並較佳接近或等於零。在經本發明該組成物塗覆、固化並接觸微生物之實例表面中,較佳不具有抑制區,但是仍可防止微生物在經處理表面上之生長或群集。
可選擇性將所形成非濾出型抗微生物劑塗覆之表面製成具高潤滑性。可藉酯、醚、硫酯、硫醚、胺基甲酸酯、胺基甲酸乙酯、尿素、醯胺或習用於聚合反應(諸如自由基聚合反應)之鍵合機制,或將不飽和碳-碳鍵轉化成高碳分子分支鏈碳-碳單鍵而確立該聚合物與抗微生物劑之共價鍵聯。具有本發明預防微生物附著性質之在基質上的該聚合物表面塗層較佳可承受對濾出溶液之大量暴露且不會損失其抗微生物性質。如藉生物分析所測定,該等經塗覆基質較佳不會形成抑制區。合適的載體溶劑可包括水、甲基乙基酮、N-甲基吡咯啶酮、四氫呋喃、乳酸乙酯、二氯甲烷、氯仿、乙酸乙酯、丙二醇甲基醚、丙二醇甲基醚乙酸酯、醇、醚、酯、芳香族化合物、氯化烴、烴及彼等之混合物。該組成物較佳用於治療以下各物之表面:醫用裝置、外科敷料、水凝膠、織物、紙、布、金屬、玻璃、塑料等。
本發明一方面係有關於形成可固化抗微生物膜之組成物,其包含聚合物基質、載體溶劑及至少一種長鏈化合物,該長鏈化合物包含一種一旦蒸發該載體溶劑並乾燥或固化該組成物時可以與該基質形成化學鍵之官能基。該官能基較佳選自由胺、硫醇、羧基、醛、羥基及彼等之組合所組成之群組。一旦乾燥或固化該組成物時,該至少一種長鏈化合物為非濾出型且能穿透微生物之細胞壁並可防止維生物群集在該固化組成物之表面上。經過一段時間後,該至少一種長鏈化合物亦具有足以穿過沉積於該固化組成物表面上之有機碎屑的長度。
該聚合物質基較佳包括至少一種聚胺基甲酸乙酯預聚物,該聚胺基甲酸酯預聚物包含至少一種一旦乾燥或固化該塗料組成物時可以直接或經由交聯劑而與長鏈化合物之該官能基形成化學鍵(較佳為共價鍵)的官能基。
該長鏈化合物較佳為選自由陰離子、陽離子及非離子表面活化劑所組成之群組的表面活化劑。該成膜型組成物包括至少兩種表面活化劑之組合。該具有至少兩種表面活化劑之組合可包括具有不同鏈長之表面活化劑。該表面活化劑較佳為陽離子表面活化劑且該陽離子表面活化劑較佳為四級銨化合物。
該四級銨化合物較佳選自以下所組成之群組:烷基羥乙基二甲基氯化銨、聚四級銨11、乙烯基吡咯啶酮及二甲胺基甲基丙烯酸乙酯之季鹼化共聚物、聚四級銨16、聚四級銨44、乙烯基吡咯啶酮及季鹼化乙烯基咪唑之組合、聚四級銨55、乙烯基吡咯啶酮及二甲胺基乙基之季鹼化共聚物、N,N-二甲基-N-十二基-N-(2-羥基-3-磺丙基)銨甜菜鹼、N-烷基酸醯胺丙基-N,N-二甲基-N-(3-磺丙基)銨甜菜鹼、具有長鏈烷基之3-氯-2-羥丙基-烷基-二甲基氯化銨,及彼等之組合。
該表面活化劑較佳以至少約15埃(),更佳至少約30埃且最佳至少約60埃自固化塗層之表面突出。根據所欲應用及有機積聚之厚度,該表面活化劑經選用可調整其自該固化塗層表面突起並超越該等有機碎屑之距離。該等有機碎屑可選自由死微生物細胞、蛋白質狀積聚及彼等之組合所組成之群組。
該成膜組成物較佳包括親水型水溶性有機單體、寡聚物、預聚物、聚合物或一類型之共聚物,且當塗覆組成物及未經塗覆表面各經水或水性溶液弄濕時,與該未經塗覆表面比較,該成膜組成物之含量足以使該經塗覆組合物之摩擦力減少至少約70%。摩擦力較佳減少至少約80%,更佳至少約90%且最佳至少約95%。
本發明另一方面係有關於可固化抗微生物塗料組成物,以該組成物之重量為基準計,其包含自約0.01%至約20%之至少一種聚胺基甲酸乙酯預聚物、自約99.89%至約75%之至少一種可至少部份溶解該聚胺基甲酸乙酯預聚物之載體溶劑,及自約0.01%至約10%之至少一種具有選自由胺、硫醇、羧基、醛及羥基所組成之群組之官能基的長鏈有機化合物,其中該聚胺基甲酸乙酯預聚物含有至少一種於該載體溶劑蒸發時可以與該長鏈有機化合物之官能基形成化學鍵之官能基。在另一實施例中,該組成物包括可以與該聚胺基甲酸乙酯及長鏈有機化合物之官能基交聯之交聯劑。該化學鍵較佳為共價鍵。
該長鏈有機化合物可以是選自由陰離子、陽離子及非離子表面活化劑所組成之群組之類型的表面活化劑。該長鏈有機化合物較佳為陽離子表面活化劑,且該陽離子表面活化劑較佳為四級銨化合物。以該組成物之重量為基準計,該四級銨化合物較佳以自約0.01%至約5%之含量存在。
在一較佳方面中,本發明係有關於可固化抗微生物塗料組成物,以該組成物之重量為基準計,其包含自約0.01%至約20%之至少一種聚胺基甲酸乙酯預聚物;自約99.89%至約75%之至少一種可至少部份溶解該聚胺基甲酸乙酯預聚物之載體溶劑;自約0.01至約40%之親水性組份,其包含衍生自以下之親水性有機單體、寡聚物、預聚物、聚合物或共聚物:乙烯醇、N-乙烯基吡咯啶酮、N-乙烯基內醯胺、丙烯醯胺、醯胺、苯磺酸、乙烯基丁醛與N-乙烯基吡咯啶酮之組合、甲基丙烯酸羥乙酯、丙烯酸、乙烯基甲醚、乙烯基吡啶鎓鹵化物、甲基纖維素、乙基纖維素、羧甲基纖維素、羥乙基纖維素、羥丙基纖維素、羥甲基乙基纖維素、羥丙基甲基纖維素、乙酸纖維素、硝酸纖維素、澱粉、明膠、白蛋白、酪蛋白、樹膠、藻酸鹽、(甲基)丙烯酸羥乙酯、(甲基)丙烯酸羥丙酯、乙二醇(甲基)丙烯酸酯(例如三乙二醇(甲基)丙烯酸酯及(甲基)丙烯醯胺)、N-烷基(甲基)丙烯醯胺(例如N-甲基(甲基)丙烯醯胺及N-己基(甲基)丙烯醯胺)、N-N-二烷基(甲基)丙烯醯胺(例如N,N-二甲基(甲基)丙烯醯胺及聚-N,N-二丙基(甲基)丙烯醯胺)、N-羥烷基(甲基)丙烯醯胺聚合物(諸如聚-N-羥甲基(甲基)丙烯醯胺及聚-N-羥乙基(甲基)丙烯醯胺),及N,N-二羥烷(甲基)丙烯醯胺聚合物(諸如聚-N,N-二羥乙基(甲基)丙烯醯胺)、醚多元醇、聚氧化乙烯、聚氧化丙烯,及聚(乙烯醚)、烷基乙烯基碸、烷基乙烯基碸-丙烯酸酯或彼等之組合;及自約0.01%至約5%之至少一種四級銨化合物,且其具有以下化學式:
其中:L代表烴基,其包含至少一種一旦藉蒸發該載體溶劑而固化該塗料組成物時可以與該聚胺基甲酸乙酯預聚物形成化學鍵之官能基,且其度長足以在經過一段時間後使該至少一種四級銨化合物穿過並超越沉積在該固化塗覆組成物表面上之有機碎屑,其中藉蒸發該載體溶劑,該官能基可以直接或藉可交聯該四級銨化合物與聚胺基甲酸乙酯預聚物之交聯劑而與該聚胺基甲酸乙酯預聚物反應;且R1
、R2
及R3
中至少一種代表可穿透微生物之細胞壁並殺滅該微生物之烴基。
在一實施例中,L具有介於1與約40個原子間之鏈長;R1
及R3
獨立具有介於1與約4個原子間之鏈長;且R2
具有介於約12與約23個原子間之鏈長。L較佳具有介於約5與30個原子間且更佳介於約10與25個原子間之鏈長。
在一實施例中,該聚胺基甲酸乙酯預聚物含有至少一種選自以下所組成之群組之官能基:反應性異氰酸根、嵌段異氰酸根、硫異氰酸根、羧基、胺基、乙烯基及彼等之組合。該至少一種官能基較佳選自由反應性異氰酸根、嵌段異氰酸根及硫異氰酸根所組成之群組。
該塗料組成物亦可包括一種選自以下所組成之群組之改質聚合物:聚酯、聚醇酸、順丁烯二酸酐聚合物、順丁烯二酸酐共聚物、多元醇、聚胺、聚醯胺、聚丙烯酸酯、聚乙烯醇、聚乙酸乙烯酯、聚葡萄糖醯胺、聚葡萄糖胺、聚乙烯基吡咯啶酮、彼等之共聚物及彼等之組合。
該親水組份較佳包含選自由N-聚乙烯基吡咯啶酮、聚乙烯醇、烷基多元醇、烷氧基多元醇、多醣、聚葡萄糖醯胺、聚葡萄糖胺及彼等之組合所組成之群組的聚合物、共聚物或預聚物。
以取代該載體溶劑之組成物重量為基準計,該親水組份係以自約0.2%至約15%且更佳約1%至約12%之含量存在。該親水聚合物、共聚物或預聚物最佳為聚乙烯基吡咯啶酮(PVP)。該PVP之存在量較佳至少約等於該四級銨化合物之含量。
就使用交聯劑之情況而言,該交聯劑較佳選自以下所組成之群組:吖丙啶(aziridine)、碳化二醯亞胺、蜜胺、經取代蜜胺、蜜胺衍生物、多官能性醇、多官能性醛、多官能性胺、多官能性異氰酸酯及彼等之組合。以取代該載體溶劑之組成物重量為基準計,該交聯劑較佳以自約0.001%至約5%且更佳約0.1%至約2.5%之含量存在。
該塗料組成物亦可包括反應增強觸媒。較佳觸媒包括選自由錫有機化合物、鈷有機化合物、三甲胺、三乙胺及彼等之組合成所組成之群組的觸媒。較佳觸媒實例包括二月桂酸二丁錫及辛酸鈷。
該載體溶劑可選自以下所組成之群組:水、甲基乙基酮、N-甲基吡咯啶酮、四氫呋喃、二氯甲烷、氯仿、乙酸乙酯、丙二醇甲醚、丙二醇甲醚乙酸酯、二丙酮醇、醚、酯、芳香烴、氯化烴、直鏈烴及彼等之組合。
在上式中,L之長度較佳足以使大量正電荷之氮原子停留在死微生物(或有機碎屑)上,該等死微生物係在使用該固化組成物時、聚集在該固化組成物之表面上。當使用該固化組成物時,較佳至少約20%,更佳至少約30%且最佳至少約50%該等正電荷氮原子停留在積聚於該固化組成物表面上之死微生物及碎屑上。該等R基團經選用以具有能有效地彼此配合之類型及鏈長,藉此該總四級銨化合物能有效穿透並破壞微生物細胞壁以導致細胞死亡。
該至少一種四級銨化合物較佳選自以下所組成之群組:烷基羥乙基二甲基氯化銨、聚四級銨11、乙烯基吡咯啶酮與二甲胺基乙基甲基丙烯酸酯之季鹼化共聚物、聚四級銨16、聚四級銨44、乙烯基吡咯啶酮與季鹼化乙烯基咪唑之組合、聚四級銨55、乙烯基吡咯啶酮與二甲胺基乙基之季鹼化共聚物、N,N-二甲基-N-十二基-N-(2-羥基-3-磺丙基)銨甜菜鹼、N-烷基酸醯胺基丙基-N,N-二甲基-N-(3-磺丙基)-銨甜菜鹼、具長鏈烷基之3-氯-2-羥丙基-烷基-二甲基氯化銨,及彼等之組合。
該塗料組成物較佳含有至少兩種上述四級銨化合物之組合。在一較佳實施例中,該塗料組成物含有3-氯-2-羥丙基-硬脂基二甲基氯化銨與烷基羥乙基二甲基-R-氯化銨之組合。在一實施例中,該塗料組成物含有至少3種上述四級銨化合物之組合。在此實施例中,該組合較佳包括烷基羥乙基二甲基氯化銨、3-氯-2-羥丙基-椰子烷基-二甲基氯化銨及3-氯-2-羥丙基-硬脂基-二甲基氯化銨,例如Praepagen HY、Quab 360及Quab 426之組合。
該塗料組成物亦可包括另一計劃自該固化塗料組成物濾出的組份,該組份係選自以下所組成之群組:抗微生物化合物、殺生物劑、抗生素、藥物、維生素、殺真菌劑、制真菌劑、殺病毒劑、殺菌劑、殺精子劑、治療劑、植物萃取物及彼等之組合。
本發明又另一方面係有關於非濾出型抗微生物固體表面塗料,其包含與具有下式之四級抗微生物化合物共價鍵結之固體聚合物基質:
其中:該聚合物基質包含固化聚胺基甲酸乙酯;X代表-O-、-S-、-CO-、-COO-、-NH-CO-或-NH-;L代表具有鏈長足以將N延長約等於或超越積聚在該塗層表面上之任何蛋白質狀碎屑;N代表氮或磷;且R1
、R2
及R3
獨立代表碳鏈,其中至少一R基之長度跑以穿透並破壞微生物細胞壁而導致該細胞死亡。
在一實施例中,R1
及R2
獨立代表具有自1至約4個原子之鏈長的烴基,且R3
代表具有約12至約23個原子之烴基。
本發明又另一方面係有關於用於導入人體或動物體內之醫用裝置,其包括在該裝置之至少一表面上的抗微生物塗層,該抗微生物塗層包括:包含聚胺基甲酸乙酯組份之聚合物基質;及至少一種與該聚胺基甲酸乙酯化學性鍵結之長鏈表面活化劑,該表面活化劑係自該抗微生物塗層之表面突起且由於被導入人體或動物體內,所以具有經過一段時間後可穿過沉積在該微生物塗層表面之有機碎屑的足夠長度。該表面活化劑係非濾出型且可穿透微生物之細胞壁並防止微生物群聚在該抗微生物塗層之表面上。該長鏈表面活化劑較佳與該聚胺基甲酸乙酯組份共價鍵結。
該醫用裝置亦可包括衍生自以下之親水性有機單體、寡聚物、預聚物、聚合物或共聚物:乙烯醇、N-乙烯基吡咯啶酮、N-乙烯基內醯胺、丙烯醯胺、醯胺、苯磺酸、乙烯基丁醛與N-乙烯基吡咯啶酮之組合、甲基丙烯酸羥乙酯、丙烯酸、乙烯基甲醚、乙烯基吡啶鎓鹵化物、甲基纖維素、乙基纖維素、羧甲基纖維素、羥乙基纖維素、羥丙基纖維素、羥甲基乙基纖維素、羥丙基甲基纖維素、乙酸纖維素、硝酸纖維素、澱粉、明膠、白蛋白、酪蛋白、樹膠、藻酸鹽、(甲基)丙烯酸羥乙酯、(甲基)丙烯酸羥丙酯、乙二醇(甲基)丙烯酸酯(例如三乙二醇(甲基)丙烯酸酯及(甲基)丙烯醯胺)、N-烷基(甲基)丙烯醯胺(例如N-甲基(甲基)丙烯醯胺及N-己基(甲基)丙烯醯胺)、N-N-二烷基(甲基)丙烯醯胺(例如N,N-二甲基(甲基)丙烯醯胺及聚-N,N-二丙基(甲基)丙烯醯胺)、N-羥烷基(甲基)丙烯醯胺聚合物(諸如聚-N-羥甲基(甲基)丙烯醯胺及聚-N-羥乙基(甲基)丙烯醯胺),及N,N-二羥烷(甲基)丙烯醯胺聚合物(諸如聚-N,N-二羥乙基(甲基)丙烯醯胺)、醚多元醇、聚氧化乙烯、聚氧化丙烯,及聚(乙烯醚)、烷基乙烯基碸、烷基乙烯基碸-丙烯酸酯或彼等之組合。
該醫用裝置較佳包括選自由N-聚乙烯基吡咯啶酮、聚乙烯醇、烷基多元醇、烷氧基多元醇、多醣、聚葡萄糖醯胺、聚葡萄糖胺及彼等之組合所組成之群組的親水聚合物、共聚物或預聚物。
該表面活化劑較佳為一種選自由陰離子、陽離子及非離子表面活化劑所組成之群組的類型。在一實施例中,該抗微生物塗層包括至少兩種表面活化劑之組合。該至少兩種表面活化劑之組合可包括具有不同鏈長之表面活化劑。該表面活化劑較佳為陽離子表面活化劑。該陽離子表面活化劑較佳為四級銨化合物。
該四級銨化合物可選自以下所組成之群組:烷基羥乙基二甲基氯化銨、聚四級銨11、乙烯基吡咯啶酮與二甲胺基乙基甲基丙烯酸酯之季鹼化共聚物、聚四級銨16、聚四級銨44、乙烯基吡咯啶酮與季鹼化乙烯基咪唑之組合、聚四級銨55、乙烯基吡咯啶酮與二甲胺基乙基之季鹼化共聚物、N,N-二甲基-N-十二基-N-(2-羥基-3-磺丙基)銨甜菜鹼、N-烷基酸醯胺基丙基-N,N-二甲基-N-(3-磺丙基)-銨甜菜鹼、具長鏈烷基之3-氯-2-羥丙基-烷基-二甲基氯化銨,及彼等之組合。
該表面活化劑較佳自該抗微生物塗層之表面突出至少約15埃,更佳至少約30埃且最佳至少約60埃。
該抗微生物塗層較佳包括親水聚合物、一類型之共聚物或預聚物,且當該塗層及未經塗覆表面各經水或水性溶液弄濕時,與該未經塗覆表面比較,該親水聚合物、一類型之共聚物或預聚物的含量足以使該塗層之摩擦力減少至少70%。摩擦力較佳減少至少約80%,更佳至少約90%且最佳至少約95%。
本發明另外目標、優點及新穎特徵可部份揭示在說明文及下述實例中,且部份可藉熟悉本項技藝者在檢查下文後而瞭解或可藉本發明之實踐而瞭解。可藉在附加申請專利範圍中特別指示之儀器配置及組合而實現及獲得本發明之目標及優點。
本發明係有關於非濾出型抗微生物塗料組成物,其可藉乾燥並蒸發該組成物之載體溶劑而得到具有預防細菌附著表面塗層的表面。本發明亦包括製備及施加本發明該組成物之方法。
如本專利說明書及其申請專利範圍內所使用,以下名詞具有下述之特殊意義及定義:如文中使用,該名詞“化學鍵”有意廣義地解釋為不僅包括共價鍵結及離子鍵結,而且包括交互作用,諸如凡得瓦力(van der waals forces)及氫鍵結,其交互作用之程度使其不能藉與水之水解交互作用而處理以致導致原先連接之抗微生物劑濾出並形成會產生抑制區之經分裂抗微生物實體。
如文中使用,該名詞“抗微生物劑”意欲包括可進行生物活動或能有效對抗微生物之物質。適於本發明之抗微生物分子團可包括在該塗料組成物固化後可得到抗微生物非濾出型持久膜(其作用並不會形成由於濾出所導致的抑制區)之陰離子、陽離子及非離子表面活化劑。
根據本發明之該塗料組成物較佳包括含可以與特定長鏈陰離子、陽離子及非離子表面活化劑化合物對胺、硫醇、羧基、醛或羥基活性基團共價鍵結之官能基的聚合物基質。該特定長鏈化合物之長度足以在使用期間經一段時間後穿過沉積在所形成塗層上之有機碎屑。藉固化該塗料組成物,這些長鏈化合物可變成非濾出型且可穿透微生物之細胞壁並破壞細胞機能活性以防止微生物群聚在該塗覆表面上。
該長鏈抗微生物劑可包括未經取代胺分子團、羥基分子團、醛或可以與胺分子團形成共價鍵之化學分子團(諸如醛分子團、環氧化物分子團或異氰酸根分子團)或可以與胺分子團形成離子鍵之化學分子團(諸如磷酸根分子團、硫酸根分子團或羧酸根分子團)或任一或多種這些分子團單獨或合併之任何可能組合。此外,如文中使用,該名詞“抗微生物分子”意指任一或多個抗微生物分子單獨或不同微生物劑之組合。而且,該抗微生物劑之未經取代胺機能可作為藉與光氣或光氣衍生物進行之已知反應而調節成更具反應性異氰酸根機能之起始機能。通常,在該聚合物基質內或在該抗微生物分子團內之位置不受限制下,個別官能基可存在於該聚合物主鏈、該交聯劑或該抗微生物劑以補充該官能基。
如文中使用,該名詞“不可濾出”意指該塗層不再釋放大量具生物活性濃度之原有抗微生物分子團,亦即就抑制區而言,其不再具殺生物性。該等濾出濃度係低於在水性溶液中之實際有效性含量,因此並不能控制微生物生長。在鹽水溶液或去礦質水之存在下,使經本發明組成物塗覆之試驗試樣進行大量浸濾,費時至少28天,然後進行生物測試。經28天浸濾循環後,根據本發明之塗料並不會失去其效力,其確認該抗微生物分子團與該表面鍵結。當a.)未檢測出抑制區及b.)經24小時微生物接觸及在經本發明該等組成物塗覆之浸濾表面培育5天後並無微生物附著或生長時,藉微生物測試而確認經28天浸濾循環後該非濾出型抗微生物狀態。
根據本發明之該等抗微生物塗料一旦乾燥並固化時,可得到能對抗目標微生物之長期效力(較佳至少約3個月)的非濾出型抗微生物表面。該效力較佳維持至少約6個月,更佳至少約9個月且最佳至少約1年。該等目標微生物可包括大腸桿菌(Escherichia coli)及/或金黃色葡萄球菌(Staphylococcus aureus)。
在本發明一實施例中,具有反應性基團之聚合物基質係與特定抗微生物分子之反應性基團對應物反應以藉將該原有抗微生物劑轉化成抗微生物表面活性聚合物塗料(其不具有以浸濾為主之作用模式)而在非濾出型聚合物基質內形成對的共價鍵結分子團。在另一實施例中,該原共價鍵聯可藉交聯劑而產生。因此,可藉以下各物之機能而使該聚合物與抗微生物劑共價鍵合:酯、醚、硫酯、硫醚、胺基甲酸酯、胺基甲酸乙酯、尿素、醯胺或習用於聚合反應(諸如自由基聚合反應)之鍵聯機制或使不飽和碳-碳鍵轉化成高碳分子分支鏈單碳-碳單鍵或藉助於交聯劑。可選擇性地將所形成非漏出型抗微生物塗覆表面製成具高潤滑性。
本發明亦提供使抗微生物聚合物塗料附著於基質表面及對應醫用裝置之方法。本發明提供製備具有至少一種形成抗微生物表面之抗微生物劑固定於聚合物表面上的醫用裝置之方法。本發明之一方法包括轉化含胺官能性物質(RNH2
)之抗微生物分子並合併該胺官能性物質及醛分子團、硫酸根分子團或羧酸根分子團(其可以與該胺官能性物質形成化學鍵)以將兩種物質鍵合在一起而在具有或未具有潤滑性質之醫用裝置表面上形成固定化抗微生物或制微生物性生物分子。
本發明另一種方法包括轉化含羥基官能性物質(ROH)之抗微生物分子並合併該羥基官能性物質及環氧化物分子團、異氰酸根分子團、磷酸根分子團、硫酸根分子團或羧基分子團(其可以與該羥基官能性物質形成化學鍵)以鍵合這兩種物質而在具有或未具有潤滑性質之醫用裝置表面上形成固定化抗微生物非濾出型聚合物。本發明亦包括使用此等經改質抗微生物聚合物以塗覆由聚碳酸酯、PVC、聚胺基甲酸乙酯、玻璃、陶瓷等所製成之薄片材料。所形成表面不僅具抗微生物性及不會形成抑制區(無濾出),而且具有抗霧及抗霜性質。此原塗料之應用包括溫室、清潔室牆壁、食物處理室之牆壁、冷凍庫門等。
本發明另一種方法包括交聯反應性抗微生物劑以形成可固定該抗微生物劑之非濾出型抗微生物表面塗料聚合物。適於固定該抗微生物劑並可形成抗微生物聚合物表面之交聯劑包括具有異氰酸根、羧基、丙烯酸衍生物、醛基、醇基、吖丙啶或碳化二醯亞胺中之至少兩種官能基的多官能性分子。該半交聯組成物材料可作為抗微生物聚合物材料或抗微生物塗料。一旦乾燥並固化時,其可完全交聯。此外,為了支持的抗微生物或治療性能之故意且控制性溶析,此等交聯材料可進一步經修飾以選擇性含有不容易完全固定化、不容易與前述交聯劑形成共價鍵結或交聯之另外抗微生物劑、抗生素或藥物。
連接適於非濾出型抗微生物作用模式之抗微生物劑的較佳方法為藉使得自聚胺基甲酸乙酯預聚物之可用游離態異氰酸根基團與具有長鏈分子團之特定抗微生物四級銨化合物的胺或羥基進行反應而形成共價鍵。若根據前述“不可濾出”之定義而檢測無微生物表面時,離子鍵結或其它化學交互作用僅用於本發明該等組成物。
已發現並非所有四級銨化合物具有非濾出型且同時可維持該非附著性抗微生物效力之所欲性質。
令人驚訝地,已發現具有下式之四級銨化合物可符合這些需求:
其中該等基團R1、R2或R3中至少一種具有足以穿透微生物之細胞壁的長度,因此可殺滅細菌並預防微生物群集在該等固化組成物之表面上;且R4之長度足以使該等其它R基團中至少一種在經過一段時間後可穿過沉積在該固化組成物表面上之有機碎屑,且一旦該組成物乾燥或固化時,R4上之該OH官能基可以與該塗料組成物之聚合物基質共價鍵結。R4之長度足以使N在經過一段時間後,位於或穿過沉積在該固化組成物表面上之任何有機碎屑。另外,該R4基團可含有反應增強基團,其係位於R4中之反應性基團的α位置。這些已溶於水之具有反應基團的合適四級銨化合物係用於與該組成物之聚合物基質內之含殘留異氰根的聚胺基甲酸乙酯共價鍵結。
合適的四級胺化合物具有3種重要的構造:(a)其含有可以與該PU預聚物之殘餘異氰酸根基團反應以分別形成尿素、胺基甲酸酯及硫胺基甲酸酯之官能基,諸如一級胺、羥基或硫醇基;(b)該具有異氰酸根反應官能基之碳鏈之長度足以使該四級化合物穿過任何蛋白質狀積聚物;及(c)該化合物含有至少一種可穿刺微生物細胞壁之另外碳鏈。在一實施例中,該另外碳鏈為13個碳原子或更多碳原子。
該至少一種四級銨化合物較佳選自以下所組成之群組:烷基羥乙基二甲基氯化銨(Praepagen HY)、聚四級銨11、乙烯基吡咯啶酮與二甲胺基甲基丙烯酸乙酯之季鹼化共聚物、聚四級銨16、聚四級銨44(乙烯基吡咯啶酮及季鹼化乙烯基咪唑)、聚四級銨55(乙烯基吡咯啶酮與二甲胺基乙基之季鹼化共聚物)、N,N-二甲基-N-十二基-N-(2-羥基-3-磺丙基)銨甜菜鹼(Ralufon DL-OH)、N-烷基酸醯胺基丙基-N,N-二甲基-N-(3-磺丙基)-銨甜菜鹼(Ralufon CAS-OH)及具有長鏈烷基之3-氯-2-羥丙基-烷基-二甲基氯化銨。較佳的長鏈烷基包括十二基(例如,Quab 342)、椰子烷基(例如Quab 360)及/或硬脂基(例如Quab 426)。
該塗料組成物較佳含有至少兩種上述四級銨化合物之組合。較佳組合包括以下:(1)Ralufon DL-OH及Quab 360;(2)Praepagen HY及Quab 426;(3)Quab 342及Ralufon CAS-OH;及(4)Praepagen HY及Quab 360。該塗料組成物更佳含有3-氯-2-羥丙基-硬脂基二甲基氯化銨(得自Degussa之Quab 426)及烷基羥乙基二甲基-R-氯化銨(得自Clarient之Preapagen HY)之組合。該等四級化合物之組合的比率較佳互為約3:1至約1:3。
該塗料組成物亦較佳包括衍生自以下之親水性有機單體、寡聚物、預聚物、聚合物或共聚物:乙烯醇、N-乙烯基吡咯啶酮、N-乙烯基內醯胺、丙烯醯胺、醯胺、苯磺酸、乙烯基丁醛與N-乙烯基吡咯啶酮之組合、甲基丙烯酸羥乙酯、丙烯酸、乙烯基甲醚、乙烯基吡啶鎓鹵化物、甲基纖維素、乙基纖維素、羧甲基纖維素、羥乙基纖維素、羥丙基纖維素、羥甲基乙基纖維素、羥丙基甲基纖維素、乙酸纖維素、硝酸纖維素、澱粉、明膠、白蛋白、酪蛋白、樹膠、藻酸鹽、(甲基)丙烯酸羥乙酯、(甲基)丙烯酸羥丙酯、乙二醇(甲基)丙烯酸酯(例如三乙二醇(甲基)丙烯酸酯及(甲基)丙烯醯胺)、N-烷基(甲基)丙烯醯胺(例如N-甲基(甲基)丙烯醯胺及N-己基(甲基)丙烯醯胺)、N-N-二烷基(甲基)丙烯醯胺(例如N,N-二甲基(甲基)丙烯醯胺及聚-N,N-二丙基(甲基)丙烯醯胺)、N-羥烷基(甲基)丙烯醯胺聚合物(諸如聚-N-羥甲基(甲基)丙烯醯胺及聚-N-羥乙基(甲基)丙烯醯胺),及N,N-二羥烷(甲基)丙烯醯胺聚合物(諸如聚-N,N-二羥乙基(甲基)丙烯醯胺)、醚多元醇、聚氧化乙烯、聚氧化丙烯,及聚(乙烯醚)、烷基乙烯基碸、烷基乙烯基碸-丙烯酸酯或彼等之組合。
該塗料組成物更佳包括選自由聚乙烯基吡咯啶酮、聚乙烯醇、烷基多元醇、烷氧基多元醇、多醣、聚葡萄糖醯胺、聚葡萄糖胺及彼等之組合所組成之群組的親水聚合物、共聚物或預聚物。以取代載體溶劑之該組成物重量為基準計,該親水聚合物、共聚物或預聚物之存在量較佳為自約0.1%至約40%且更佳自約0.2%至約15%。該親水聚合物、共聚物或預聚物最佳為聚乙烯基吡咯啶酮(PVP)。
就如上述之聚胺基甲酸乙酯、四級銨化合物及載體溶劑之組合而言,咸信該等親水聚合物非可預期地可增強該抗微生物塗料之性能。已發現當該固化塗料移入經水解且活化之塗料內時,含某一種四級銨之塗料需要特定量之PVP才能確保合適活化作用。在獲得顯著潤滑性之前,該PVP之需要量可以是至少與該四級化合物相等之數量。
若無特定潤滑性需求,較佳PVP濃度為該塗料組成物之約0.1至約5%。若需要高潤滑性,則較佳PVP濃度為該塗料組成物之約2至約12%。
雖然不想受限於理論,一般相信需要該親水聚合物與水之間的偶極-偶極相互作用以沿著該PVP複合物穿透而將該四級銨複合物移入垂直的位置內。咸信其可藉使該抗微生物化合物自固化塗料之表面突起而增強該固化組成物之抗微生物機能。
在一實施例中,該塗料組成物亦可包括至少一種用於增強該塗料組成物及/或在該塗覆表面上所形成塗層之性能的佐劑。
該佐劑較佳選自表面活化劑或潤濕劑、乳化劑、染劑、顏料、著色劑、UV吸收劑、自由基清除劑、抗氧化劑、自由基起始劑、抗蝕劑、光學增亮劑、反應性或示蹤螢光劑、漂白劑、漂白活化劑、漂白觸媒、非活化酶、酶安定系統、螯合劑、塗料佐劑、金屬觸媒、金屬氧化物觸媒、有機金屬觸媒、成膜促進劑、硬化劑、結合加速劑、助流劑、均染劑、消泡劑、潤滑劑、無光澤顆粒、流變改質劑、增稠劑、導電性或非導電性金屬氧化物顆粒、磁性顆粒、抗靜電劑、pH控制劑、香料、防腐劑、殺生物劑、殺蟲劑、抗垢劑、滅藻劑、殺細菌劑、殺菌劑、消毒劑、殺真菌劑、生物影響劑、維生素、藥物、治療劑或彼等之組合。
在一實施例中,以該塗料組成物之重量為基準計,用於增強性能之該佐劑濃度為自0.001%至10%,較佳自0.01%至5%。
在一實施例中,該塗料組成物含有自0重量%至50重量%有機溶劑及自0.5重量%至95重量%水,較佳1重量%至50重量%。
可將該塗料組成物塗覆在選自以下所組成之群組之物件的表面上:金屬、金屬合金、塑膠、玻璃、人的皮膚、動物皮或纖維狀材料。該物件亦可以是用於導入人體或動物體內之醫用裝置,其包括在該裝置之至少一表面上的塗料組成物。
該醫用裝置可以是至少部份由以下各物所製成:金屬或由不銹鋼、鎳、鎳-鈷、鈦、NiTi、鉭、鎳鈦諾(nitinol)、稀土金屬、銀、金、鉑、鎢、彼等之組合組成之金屬合金,或合金群或彼等之鍍面物件。
該醫用裝置可以是至少部份由以下各物所製成:聚碳酸酯、聚醚、聚酯、聚氯化乙烯、聚苯乙烯、聚乙烯、聚丙烯、聚乙酸乙烯、聚矽氧橡膠、橡膠乳膠、聚酯-聚醚共聚物、甲基丙烯酸伸乙酯、聚矽氧、天然及合成橡膠、尼龍、PEBAX、聚醯胺或彼等之組合。
該醫用裝置可以是至少部份由玻璃,諸如眼鏡、光學透鏡、偏光鏡片、鏡子、光學反射鏡、稜鏡、石英玻璃等,所製成。
在一實施例中,係藉根據本發明之塗料組成物而塗覆該醫用裝置,其塗覆方法包括浸塗法、刷塗法、溢流塗覆法、噴塗法、桿塗法、滾輪塗覆法、電解沉積法、靜電噴塗法、電鍍法、真空處理法、壓力處理法或彼等之組合。
該醫用裝置可以呈以下形式:管、毛細管、金屬線、薄片、線圈、棒、格子或金屬線之網狀物。
該醫用裝置可以是外科棒、骨科矯形植入物、導引線、導線管、旋彎導引管、旋彎導管、消耗性或非消耗性移植片固定模、電極線圈、針、葉片、心臟調整器或類似金屬醫用裝置。
該醫用裝置亦可以是錠劑、膠囊、管狀物、毛細管、薄片、纖維、傷口敷料、組織分離器、縫線、汽球、箔、導管、透析導管、尿導管、引導賽、傷口引流管、移植片固定模或類似醫用裝置。
在另一實施例中,該佐劑係選擇性與該塗料組成物化學性鍵結及/或物理性併入該塗料組成物中或併入該物件表面上之最後塗層內。
在又另一實施例中,該佐劑可選擇性為一種選自由以下所組成之群組的防腐劑:對羥基苯甲酸酯(paraben)、甲醛釋放劑、鹵烷基物、鹵炔基物、烷基酸、芳基酸、異噻唑烷酮、四級銨化合物(quat)、氧化鋅、鋅有機物、碘、帕吡酮(povidone)-碘、氯己啶(chlorhexidine)、溴硝丙二醇波(bronopol)、三氯生(triclosan)、布羅崔瑪唑(clotrimazol)、米可納唑(miconazole)、丙可納唑(propiconazole)、特布可納唑(tebuconazole)、托萘酯(tolnaphtate)、克里氫醌(clioquinol)、膠態銀、銀複合物及銀鹽或彼等之組合。
在另一實施例中,該佐劑可選擇性為選自以下所組成之群組的抗微生物劑:抗生素、防腐劑、消毒劑,其包括四環素、利福黴素(rifamycin)、雷帕黴素(rapamycin)、大環內酯、青黴素、頭孢菌素、β-丙醯胺抗生素、胺基糖苷、氯黴素(chloramphenicol)、磺醯胺、糖肽、喹諾酮(quinolone)、西普福辛(ciprofloxacin)、梭鏈泡酸、甲氧苄胺嘧啶(trimethoprim)、甲硝噠唑(metronidazole)、克林達黴素(clindamycin)、木匹羅辛(mupirocin)、多烯(polyene)、氮(azote)、氟康唑(fluconazole)、β-內醯胺抑制劑等。
在另一實施例中,該佐劑可選擇性為選自以下所組成之群組的治療劑:鎮痛劑;抗發炎劑;局部抗嘌呤劑;止癢劑;非類固醇;對位乙醯胺基酚(acetaminophen);乙基水楊酸酯;樟腦;丁苯羥酸(bufexamac);異丁苯丙酸(ibuprofen);吲哚美辛(indomethacin);類固醇,諸如氫皮質酮、地索耐德(desonide)、安西諾隆(triamcinolone)縮丙酮化物、倍它米松(betamethasone)戊酸酯、貝它米松二丙酸酯、貝它米松苯甲酸酯、氯倍塔索(clobetasol)丙酸酯、哈西耐德(halcinonide)、去羥米松(desoximethasone)、安西耐德(amcinonide)、氟西耐德(fluocinonide)、氟安瑞里德(fluandrenolide)、阿氯米松(alclometasone)二丙酸鹽、氟西諾隆(flucinolone)縮丙酮化物、二氟拉松(diflorasone)二乙酸酯、莫美塔松(mometasone)糠酸酯、氟米隆(fluorometholone)、氯可托隆(clocortolone)三甲基乙酸酯、安西諾隆縮丙酮化物、哈西耐德(halcinonide);皮膚病藥劑;蒽三酚(anthralin)(煤焦油萃取物);角質溶解劑(水楊酸);尿素;局部麻醉劑,諸如利多卡因(lidocaine)、苯并卡因(benzocaine);抗痤瘡劑,諸如過氧化二苯甲醯、維生素A衍生物;疣去除劑,諸如水楊酸、乳酸等;與其它類似藥劑及彼等之環糊精複合物。
在另一實施例中,該佐劑可選擇性為選自以下所組成之群組的藥物:抗形成血栓藥物或抗形成血栓藥劑或血管支架再狹窄防止藥物,其包括紫杉酚、太平洋紫杉醇(paclitaxel)、太平洋紫杉醇衍生物、地塞米松(dexamethasone)及其衍生物、肝素及其衍生物、阿斯匹靈及水蛭素;氧化氮藥物衍生物;氧化氮釋放藥物;特克里莫(tacrolimus)、艾伯里莫(everolimus)、環孢黴素、西羅里莫(sirolimus)、血管肽與依諾肝素(enoxaprin)等或彼等之組合。
在另一實施例中,該佐劑可選擇性為選自以下所組成之群組的不容射線透過之化合物:泛影酸鹽(diatrizoate)、腦影酸鹽(iothalamate)、甲泛影酸鹽(metrizoate)、膽影酸(iodipamide)、三碘苯甲酸、腦影酸、三碘苯基酸、碘索拉酸(iodothalamic acid)、碘、碘化物、溴、全氟辛基溴、硫酸鈽、釤、鉀、鉍鹽(其包括氧基鹽及氧化物)、氧化鈦、氧化鋯、金、鉑、銀、鉭、鈮、鎢、銥或錸及彼等之組合。
該金屬或金屬合金物件可以是由選自以下所組成之群組的金屬或金屬合金所製成:鋁、鎂、鈹、鐵、鋅、不銹鋼、鎳、鎳-鈷、鉻、鈦、鉭、稀土金屬、銀、金、鉑、鎢、釩、銅、黃銅、青銅等或彼等之組合或彼等之鍍面物件。
該等塑膠物件可以由選自以下所組成之群組的聚合物所製成:透明或非透明聚胺基甲酸乙酯、聚碳酸酯、聚醚、聚酯、聚氯乙烯、聚苯乙烯、聚乙烯、聚丙烯、聚乙酸乙烯、聚矽氧橡膠、橡膠乳膠、聚酯-聚醚共聚物、甲基丙烯酸伸乙酯、聚矽氧、天然及合成橡膠、尼龍、聚醯胺或彼等之組合。
該等玻璃物件可以是至少部份由玻璃所製成,諸如眼鏡、光學透鏡、偏光鏡片、鏡子、光學反射鏡、稜鏡、石英玻璃、陶瓷等。
該等塑膠物件可包括罩、頭盔罩、泳鏡、外科面罩、食物包裝塑膠箔、溫室牆壁、溫室屋頂、鏡子、擋風玻璃、水下移動物體、飛機窗罩、載客氣球、手套、圍裙、海綿等。
該等玻璃物件可包括窗戶玻璃、溫室玻璃、玻璃薄片、面罩、眼鏡、光學透鏡、偏光鏡片、鏡子、光學反射鏡、稜鏡、石英玻璃、碟形天線、汽車頭燈遠近光玻璃、汽車擋風玻璃、飛機燈控玻璃、跑道照明等。
該纖維狀材料可含有金屬、玻璃、塑膠或纖維素,且可包括以可防止空氣傳播的微生物污染之濾器形式的聚合物材料(例如織造及非織造材料、此等材料上之鑄製膜、紡黏材料及電紡材料)、織物,諸如用於在自去污染方法中防止微生物群集之衣服、帷幕。
本發明該等化合物、產物及組成物可用於許多應用,其包括如上述之較佳起始物質抗微生物聚合物基質的任何已知用途。在較佳實施例中,目前所述之化合物、產物及組成物適於下述應用,諸如:a)醫用裝置表面之處理;b)內科、齒科及獸醫手術室中之表面處理;c)家庭內需要一般衛生管理的表面之處理;d)托兒所及白天照顧機構中之表面處理;e)消費品之表面處理;f)食品加工工業、化妝品製造等之表面處理;g)食品包裝材料之處理;h)農業用途之表面處理,例如種子處理、動物照顧等;及i)工業產品、化學品、顏料、油墨、染劑、樹脂、黏著劑、紡織品、紙、皮革、木材、石膏,及其它需要處理之表面的處理。
本發明可特別用以製備農業產物;清潔組成物;抗微生物海綿;抗微生物漂白劑;用於油漆、塑料或混凝土之抗微生物填料;及用以處理微生物感染為重大問題之混凝土結構體,諸如牲畜棲息處。
可經本發明該等組成物處理之表面及基質包括,但不限於:紡織品、地毯、地毯背襯、室內裝飾品、衣服、海綿、塑料、金屬、由聚矽氧、聚胺基甲酸乙酯、PVC等所製成之用於排水管之醫用裝置、透析及尿導管、膽道管及膽道支架、灌食管、醫用水凝膠、局部及經皮載體用途、具有局部及內部用途之生物可降解水凝膠、外科敷料、抗微生物抗霧被單、溫室膠布、冷凍庫門、磚石建築、矽石、砂、礬土、含水氯化鋁、二氧化鈦、碳酸鈣、木材、玻璃珠、容器、瓷磚、地板、簾、船用產品、帳篷、背包、屋頂、壁板、圍欄、鑲邊、絕緣體、牆板、垃圾容器、室外傳動裝置、水純化系統,及土壤。而且,可經本發明該等組成物處理之物件包括,但不限於:空氣過濾器及用於其製造之材料、水族槽過濾器、緩衝器墊、用於室內裝飾品之纖維填料、纖維玻璃導管板、內衣及外衣、聚胺基甲酸乙酯及聚乙烯發泡體、沙袋、柏油帆布、帆、繩、鞋、短襪、毛巾、拋棄式抹布、襪類、女性衛生產品及貼身衣服;化妝品、化妝水、乳劑、軟膏、消毒劑、木材防腐劑、塑料、黏著劑、油漆、紙漿、紙、冷卻水,及洗衣添加物與一般非食品或食品接觸表面。其它實例包括衣服之一般臭味控制、抗微生物繃帶設計、動物照顧之保護性阻隔材料,其包括乳腺炎控制、清潔室設計及食品加工室之壁面處理。
本發明之塗料亦可適於軍事用途,諸如防禦生物戰;戰機、貨物及裝運箱、包裹物、制服、軍用導管等之自去污染。
而且,以本發明該等組成物處理表面或織物後,該表面或織物可選擇性經加熱以藉蒸發載體溶劑而進一步完成該組成物與該表面或基質之交聯及鍵結。
在採收方法前或後以本發明該等組成物處理糧食作物(例如易腐的作物,諸如蔬菜、水果或殼物)可提供該糧食作物外表面之抗微生物保護作用。咸信在不會自該食物項目之黏合抗微生物塗層擴散、遷移或濾出該抗微生物劑的情況下會發生此保護作用,且可提供長期、安全及非毒性抗微生物保護作用。該方法包括在沖洗循環中,於正常清洗/水噴期間或其後或殺菁(blanching)期間或其後,處理水果及蔬菜。就最初移除微生物而言,於加工廠徹底清洗水果及蔬菜較佳。一般技術者可知先使用機械以移除土壤、用於處理生長的腐敗細菌之化學品,及其它外來物質。這些機械亦使用高速水噴以清洗該等產物。清洗後,準備原料或其它農作物以進行進一步加工,諸如殺菁,亦即於190至210℉下將該食品浸在水中或接觸蒸氣下。
在進行外科程序前或期間以本發明該等化合物、產物及組成物處理外科用手套可防止細菌群集及交叉污染。咸信該等經處理之手套可得到具有安全及非毒性抗微生物保護作用之長期抗微生物活性。較佳藉浸沒在本發明組成物中而處理外科用手套。此方法使醫生可以使用具低交叉污染危險之手套。
而且,一般技術者可根據本發明該等化合物、產物及組成物之揭示內容而進行許多其它最後用途。例如以下用途、應用及基質亦涵蓋在更特佳實施例中:處理適用於移植物以減少微生物污染之骨科矯形的植入物、皮膚或其它組織(骨、軟組織)。該組成物同樣適用於本行技藝已知之牙膏配方以經由牙齒之抗微生物治療而增強此等組成物之抗齵蛀性質。
上述抗微生物化合物、產物、組成物,及方法之較佳實施例係揭示在下述實例中。自以下實例可知本發明其它特徵,此等實例僅用於闡明,並無意作為本發明之限制。
與習知殺生物劑溶析塗料及先前技藝之所謂制細菌性非溶析組成物比較,本發明該抗微生物塗料組成物具有許多優點。固化後,本發明該抗細菌塗料組成物之有利性質為:所形成塗膜並不會濾出任何抗微生物劑;該抗微生物劑係藉該塗料聚合物基質而固化;所形成塗膜具有長期抗微生物效力;由於具非濾出型之作用模式,所以所形成塗膜無副作用或第二次毒性,就需要法規許可之產物而言。該性質很重要;可選擇性地使所形成塗膜具潤滑性以適於多種以下應用:醫療、獸醫、食品包裝、紡織品、聚合物織造、家庭、個人保健、消費品、抗霧、建築、農業及其它應用。
亦評估分子及細胞、生物衝擊之另外測試。根據標準試驗ISO 100993,第5篇,本發明該塗料並未顯示細胞毒害性效果。接觸蛋白質溶液下並未危害長期、非濾出型抗微生物性能。當在涉及組織接觸及當接觸食品蛋白質或身體蛋白質之醫療區域中施加本發明塗料時,這些研究結果特別重要。
血液接觸試驗意外地顯示對與根據本發明處理之表面接觸的血液之凝固速度有影響。當與根據本發明處理之表面接觸時,血液傾向較慢或不會凝固。
使用模擬含有微生物之膽汁流率之動態試驗程序,已發現經過至少一週,在根據本發明塗覆之表面上並無黏液或生物膜積聚。在該動態試驗中,未經塗覆試樣及具有潤滑性塗層(不含該抗微生物化合物)之試樣在一週內顯示生物膜形成。
將根據本發明之組成物塗覆至寬2厘米×長2厘米之聚胺基乙酸酯試驗試樣的一側上,風乾約10分鐘,然後烘箱乾燥並於約50至95℃下固化,費時約30分鐘。在磷酸鹽緩衝劑溶液(PBS)內清洗該等固化試樣,費時1、7、14、21及28天,並於約23℃下清洗,費時2及3個月與更久。將該等試樣放在100毫升PBS浸濾溶液中。短暫地搖動後,每週一次替換該100毫升浸濾溶液。於各時間間隔下在5毫升去礦質水中清洗該等試樣共3次,於室溫下乾燥10分鐘,然後進行微生物測試。
製備根據先前技藝對含PU及視需要選用之PVP的塗料溶液。添加含6%游離態異氰酸根基團(其係在添加前藉滴定而測定)之10%聚胺基甲酸乙酯預聚物至這些溶液。
使用25毫升之0.1N二丁基胺溶液(微過量之預計量)測定存在於該聚胺基甲酸乙酯預聚物內之該異氰酸根濃度百分比並混合15分鐘。對照溴酚藍色指示劑,再以0.1N HCl滴定該過量之二丁基胺溶液,直到發現淺黃色為止。
短暫地混合含該游離態異氰酸根之塗料溶液,然後添加5%至15%四級銨化合物之40至90%水性溶液(其含有本發明之活性基團)並再短暫混合。在第一次評估中靜置該混合物以觀察其反應性。發現在約2至4小時內,該等混合物膠化,其表示可提供實際塗覆程序之時間的慢反應速度。
以類似方法製備具有含根據本發明之抗微生物劑之反應性基質及長鏈碳-碳鏈之塗料溶液的其它試樣。在該另外含異氰酸根之聚胺基甲酸乙酯預聚物與含有抗微生物劑之該反應性基團混合約15分鐘後立即施加最終塗料溶液。該等塗料具有良好黏著性且在水或PBS存在下並不會變質。部份該等試樣具有潤滑性質。
令人驚訝地,已發現儘管水之存在,仍然與該殘留異氰酸根基團和該抗微生物劑之一級胺、羥基及硫醇官能基之競爭反應有足份交互作用。亦發現根據溫度、抗微生物劑之反應性基團及可能的催化交互作用,該最終組成物具有數小時之保存期限。施加該反應性塗料組成物至各種基質上,固化並接著經水清洗以移除任何過量之未經反應抗微生物劑。以每週為基礎,使用新PBS重複該清洗步驟以確保完全移除。
製備在無菌緩衝劑溶液中具有1×106
個細胞/毫升的大腸桿菌及綠膿桿菌與金黃色葡萄球菌之細菌懸浮液以進行微生物接觸。將25微升該懸浮液滴至陪氏培養皿(Petri dish)內之試樣上並立即經瓊脂平板覆蓋。將該培養皿封合、密封並於37℃下培養24小時。培育後,在可避免瓊脂乾燥之該閉合培養皿內5天後計算菌落之細菌生長數。以數字記錄菌落計數並藉顯微術以表示在總浸濾期之各週後,各有機體之試樣及對照物的微生物生長程度。於37℃下進行該等細菌試驗,並費時24小時使細菌在經聚胺基甲酸乙酯塗覆之表面上生長。在5毫升LB肉湯溶液內培養由MicroBioLogics供應之細菌小粒(就大腸桿菌而言,其係為ATCC #25922,就金黃色葡萄球菌而言,其係為ATCC #29213),並培養4小時,然後以吸管將40微升滴至該經塗覆之聚胺基甲酸乙酯表面上。以20X顯微鏡察看結果。
使用根據美國專利US 4,467,073、US 4,642,267及US 6,054,504之配方作為對照物,該等對照物不含抗微生物劑,並具有或不具有含另外異氰酸根基團之另外聚胺基甲酸乙酯預聚物。
進行上述浸濾程序(主要為濾出之第0、7、14、21及28天)後,根據上述微生物試驗方法,該等未經塗覆之聚胺基甲酸乙酯顯示微生物,大腸桿菌及金黃色葡萄球菌,之細菌顯著過度生長或菌集。
實例2-
使用根據美國專利4,467,073號,實例1之起始塗料溶液製備適於本發明之應用的典型抗霧基劑配方,其製法如下:使2.5克聚乙烯基吡咯酮,PVP-K90,溶解在75%二丙酮醇及25%環己烷之100毫升混合物內,繼而添加1.0克二辛基磺琥珀酸鈉表面活化劑及5.0克Tycel 7351異氰酸酯預聚物(Hughson Chemicals,Lord Corporation)。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克四級銨化合物,3-氯-2-羥丙基-椰子烷基-二甲基氯化銨(Quab 360),至10克所形成溶液內。根據該組成物施加並於72℉固化24小時之塗層透明、無色、硬且具抗刮痕性,且當冷卻至32℉時並不會霧化,然後保持在含沸水之燒杯上。該塗料對聚碳酸酯、聚酯、聚甲基丙烯酸甲酯及乙酸纖維素塑料具有優異黏著性且藉預防細菌群集而具有抗微生物性質,且經長時間濾出後,效力不會耗減。於初濾出期間,未經反應之四級銨化合物之初突釋及釋放後可發現無抑制區。
實例3-
根據美國專利4,642,267,實例2製備典型醫療基劑配方,其製法如下:添加10克聚乙烯基吡咯啶酮(Kollidon 90,BASF Corp.)及33克直鏈聚胺基甲酸乙酯水性分散液(Neorez R940,Polyvinyl Chemical Industries)至47克水及10克N-甲基吡咯啶酮之混合物內。當濕潤時,自所形成黏性分散液鑄製之薄膜具潤滑性(摩擦係數為0.08)且吸水形成之彈性透明膜適於作為燒傷及創傷敷料。亦可使用該溶液以紡製纖維(其當濕潤時很靭且具彈性),且可使用該溶液以產生親水性發泡體,其係藉機械發泡或以添加的丙酮鑄製薄膜並在真空中經熱乾燥。
實例4-
添加4克聚乙烯吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克烷基羥乙基二甲基R氯化銨(R=C12)Prepagen HY(Clarient)至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片,其係藉塗覆一側,根據上述試樣製法風乾並固化,且於室溫下在鹽水溶液內浸濾,費時0、1、7、14、21及28天。在上述微生物試驗方法之條件下,浸濾7天後及接下來的數週,在該試樣上發現金黃色葡萄球菌顯著生長,但是在所有浸濾時間及接觸大腸桿菌微生物後,並未分別發現生長或群集。因此,上述組成物顯示對大腸桿菌有廣大的效力,但是7天後對金黃色葡萄球菌失效。
實例5-
(比較例)根據美國專利6,054,504,實例3之不含無濾出型抗微生物劑之典型醫療基劑配方的製法如下:使2克藉2莫耳濃度過量之二苯基甲烷二異氰酸酯(MDI)與蓖麻酸酯多元醇之反應而製成的聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)與35克甲基乙基酮、10克四氫呋喃、10克N-甲基吡咯啶酮、30克二丙酮醇、3克聚乙烯基吡咯啶酮(KOLLIDON 90F,BASF)組合。使用棉花棒將該溶液塗覆在乾淨的聚氯乙烯軟片上。將該軟片風乾,費時30分鐘,並於80℃下固化,費時30分鐘。
使用聚胺基甲酸乙酯基質取代PVC,並藉浸塗法而塗覆。根據上述試樣製法浸濾該浸塗試樣並接觸大腸桿菌微生物。於各情況下,在所述微生物試驗方法之條件下,該等試樣顯示細菌顯著過度生長。
實例6-(比較例)
根據實例5中所述之試樣製法而處理另一種浸塗試樣並在根據上述方法,在浸濾該試樣後,接觸金黃色葡萄球菌。於各情況下,在所述微生物試驗方法之條件下,該等試樣顯示細菌顯著過度生長。
實例7-
添加4克聚乙烯吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克3-氯-2-羥丙基-月桂基二甲基氯化銨,Quab 342(Degussa)至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液中浸濾。在所述微生物試驗條件下,7天浸濾後及接下來數週在該試樣上開始分別顯示金黃色葡萄球菌之生長或群集。就接觸大腸桿菌而言,在浸濾14天後開始分別顯現細菌之生長或群集。
實例8-(比較例)
使2克藉2莫耳濃度過量之二苯基甲烷二異氰酸酯(MDI)與蓖麻酸酯多元醇之反應而製成的聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)與35克甲基乙基酮、10克四氫呋喃、10克N-甲基吡咯啶酮、30克二丙酮醇、3克聚乙烯基吡咯啶酮(KOLLIDON 90F,BASF)組合。將該溶液塗覆在乾淨的聚胺基甲酸乙酯軟片之一側上,根據上述試樣之製法風乾並固化,且根據上述方法於室溫下在鹽水溶液中浸濾。在所述微生物試驗方法之條件下,於各浸濾時間後,該等試樣顯示細菌顯著過度生長。
實例9-(比較例)
添加4克聚乙烯基吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克根據美國專利5,954,869之經矽氧烷改質的四級銨化合物,3-(三甲氧基甲矽烷基)丙基二甲基十八基氯化銨至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液內浸濾。在所述微生物試驗方法之條件下,一天浸濾後並未發現細菌生長,但是7天浸濾後及接下來數週,該試樣顯示金黃色葡萄球菌之顯著細菌過度生長。
實例10-(比較例)
添加4克聚乙烯基吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克根據美國專利5,954,869之經矽氧烷改質的四級銨化合物,3-(三甲氧基甲矽烷基)丙基二甲基十八基氯化銨至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液內浸濾。在所述微生物試驗方法之條件下,經一天浸濾及接下來數週,在該試樣上發現大腸桿菌顯著生長。
實例11-(比較例)
添加4克聚乙烯基吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克經聚乙烯基吡咯啶酮改質之四級銨化合物,Styleze W-20(ISP)至10克所形成溶液內。Styleze W-20為未具有本發明之用於共價鍵結之反應性基團的經PVP改質之長鏈四級銨化合物。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,並根據上述方法於室溫下在鹽水溶液內浸濾。在所述微生物試驗方法之條件下,一天浸濾後及接下來數週在該試樣上發現大腸桿菌及金黃色葡萄球菌顯著生長。
實例12-(比較例)
添加4克聚乙烯基吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克二油酸三乙醇胺酯四級銨化合物(Preapagen 4317)(Clarient)至10克所形成溶液內。Prepagen 4317為在鏈上不具有可以與該聚合物基質形成共價鍵之反應性基團的二油酸長鏈三乙醇酯四級銨化合物。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,並根據上述方法於室溫下在鹽水溶液內浸濾。在所述微生物試驗方法之條件下,一天浸濾後及接下來數週在該試樣上發現大腸桿菌及金黃色葡萄球菌顯著生長。
實例13-
添加4克聚乙烯吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克3-氯-2-羥丙基-椰子烷基二甲基氯化銨,Quab 360(Degussa)至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液中浸濾。在所述微生物試驗條件下,7天浸濾後及接下來數週在該試樣上開始分別顯示金黃色葡萄球菌之生長或群集。就接觸大腸桿菌而言,在浸濾14天後開始分別顯現細菌之生長或群集。
實例14-
添加4克聚乙烯吡咯啶酮(Kollidon 90,BASF Corp.)及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)至75克二丙酮醇及25克甲基乙基酮之混合物內。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克3-氯-2-羥丙基-硬脂基二甲基氯化銨,Quab 426(Degussa)至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液中浸濾。在所述微生物試驗方法之條件下,所有浸濾時間後在該試樣上未顯示金黃色葡萄球菌之生長或群集。在接觸大腸桿菌下,14天浸濾後開始分別顯示細菌之生長或群集。
實例15-
藉混合48.0%甲基乙基酮、13.0%四氫呋喃、12.0%乳酸乙酯、25.0%之PVP在乳酸乙酯及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)中之12%溶液而製成抗微生物塗料。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.125克3-氯-2-羥丙基-硬脂基二甲基氯化銨,(得自Degussa之Quab 426)及0.125克烷基羥乙基二甲基-R-氯化銨(R=C12)(得自Clarient之Preapagen HY)至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液中浸濾。在所述微生物試驗之條件下進行測驗,所有浸濾時間後(就金黃色葡萄球菌而言,至高3個月,就大腸桿菌而言,至高6.5個月)在該試樣上並未分別發現該等細菌之生長或群集。
實例16-
以相同配方及試驗試樣製法重複實例15。所測試之試驗微生物為乳房鏈球菌。根據上述方法,於室溫下在鹽水溶液中浸濾。在所述微生物試驗之條件下,至高56天浸濾,在該試樣上並未發現細菌生長或群集。
實例17-(得自美國專利6,054,504之比較例)
添加13.56克四氫呋喃、12.68克乳酸乙酯及23.57克PVP K90在乳酸乙酯(2.82克聚乙烯吡咯啶酮)中之12%溶液至5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)、48.26克甲基乙基酮及0.26克海克替啶(Hexetidine)(Clariant LSM)之混合物內。混合該溶液並以吸管滴入聚胺基甲酸乙酯薄膜內,於室溫下乾燥,費時10分鐘,並於60與70℃間之溫度下在烘箱內固化,費時45分鐘。然後測試這些試樣對於革蘭氏陰性菌(大腸桿菌)及兩種革蘭氏陽性菌(金黃色葡萄球菌及表皮葡萄球菌)之抗性。於室溫下在磷酸鹽緩衝劑溶液(PBS)內浸濾一天後測試該等薄膜。結果顯示這3種細菌猖獗地生長。可得到下述結論:使用海克替啶作為共價鍵結抗細菌組份並未獲得預期效果。由於24小時失效,所以該塗層之進一步浸濾並不需要。
實例18-
於如前述之浸濾條件下,在第二裝備內長時間地測試實例15之配方。使用大腸桿菌、金黃色葡萄球菌及綠膿桿菌作為試驗微生物。在經處理之表面上,經過3個月並未發現所有微生物之菌集,然而對照物卻顯示該等細菌之生長。
實例19-
準備不銹鋼以測試抗微生物塗料,其係藉施加合適底漆並於80℃下固化10分鐘。然後添加於80℃下固化12小時之親水配方的第二層漆至該底漆之上面。將本發明之第三層抗微生物塗料塗覆在這兩道塗層之上面,本發明該備三層抗微生物塗料之製法如下:添加46.98克甲基乙基酮、13.20克四氫呋喃、12.34克乳酸乙酯、0.935克Praepagen HY(Clariant),及0.935克Quab 426(Degussa)至5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc)之化合物內。該不銹鋼塗料顯示至少兩週之抗微生物活性。
實例20-(具有非鍵合四級銨化合物之比較例)
藉混合48.0%甲基乙基酮、13.0%四氫呋喃、12.0%乳酸乙酯、25.0%乳酸乙酯-PVP溶液及2克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)而製成抗微生物塗料。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)及0.25克氯化苄烷銨(Benzalkonium chloride)(CAS # 63449-41-2)至10克所形成溶液內。施加所形成溶液至乾淨的聚胺基甲酸乙酯軟片上,其係藉塗覆一側,根據上述試樣製法風乾並固化,且根據上述方法於室溫下在鹽水溶液中浸濾。於室溫下在磷酸鹽緩衝劑溶液中浸濾3天後,該塗料溶液顯示有限之抗金黃色葡萄球菌效力。藉GC分析已發現浸濾3天後,可檢測僅1至2 ppm氯化苄烷銨之濃度,然而浸濾一天後可檢測300至400 ppm,而浸濾兩天後可檢測5至10 ppm。第2天之檢測含量相當於該四級銨化合物之約7.5 ppm的MIC含量。該塗層顯示至高約3週之抗大腸桿菌效力,且超過該時間時,有少許細菌群集。金黃色葡萄球菌顯示至高3天未生長,且其後在表面顯著的生長。
實例21-
藉混合48.0%甲基乙基酮、13.0%四氫呋喃、12.0%乳酸乙酯、25.0%乳酸乙酯-PVP溶液及2克直鏈聚胺基甲酸乙酸聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)而製成抗微生物塗料。添加0.5克直鏈聚胺基甲酸乙酯聚異氰酸酯預聚物(NORDOT黏著劑34D-2,Synthetic Surfaces,Inc.)、1.0% Praepagen HY(Clariant),及1.0% Quab 426(Degussa,CAS # 3001-63-6,CAS # 57-55-6,CAS # 7732-18-5)至10克所形成溶液內。施加所形成塗料溶液至乾淨的聚胺基甲酸乙酯薄片上,於室溫下風乾15分鐘,於80℃下固化一小時,並於室溫下使其再反應24小時,然後進行任何試驗。接著將該經塗覆之聚胺基甲酸乙酯放入熱壓機內。該熱壓循環條件為於121℃及15 psi下費時40分鐘。重複該循環共6次。各熱壓循環後,自該經塗覆及熱壓之薄片切出兩片聚胺基甲酸乙酯。每片之大約尺寸為寬一吋×長一吋。使用切出之一片以測試大腸桿菌,而另一片用於測試金黃色葡萄球菌。用吸管將40微升細菌試樣滴至該經塗覆、熱壓之聚胺基甲酸乙酯之表面上。於37℃下將該經接種之聚胺基甲酸乙酯放在恆溫箱內,費時24小時,然後察看其生長情形。經由作為滅菌之方法的6次熱壓循環,該經塗覆試樣仍具有抗大腸桿菌及金黃色葡萄球菌之效力。
實例22-
添加10.8克聚乙烯基吡啶酮/二甲基丙烯酸(ISP)至48克水中並徹底混合,pH經0.1N HCl調整至約5,並加熱該混合物,然後於70℃下維持一小時。添加1.2克該四級銨化合物,QUAB 426,攪拌該混合物,費時2小時並經1N氫氧化鈉調整至pH 7。將2.5%該組成物與2.5%TWEEN 20併入根據美國專利4,642,267之實例2的含交聯劑之標準醫用塗料配方內。添加47克水及10克N-甲基吡咯啶酮至10克聚乙烯基吡咯啶酮(Kollidon 90,BASF Corp.)、33克直鏈聚胺基甲酸乙酯水性分散液(Neorez R940,Polyvinyl Chemical Industries)及0.1克吖丙啶(CX100)內以製備該標準醫用塗料。藉以上述組成物塗覆1”×2”之聚胺基甲酸乙酯切片,於100℃下固化一小時而製成試樣,並在浸濾後測試其長期抗微生物效力。根據上述方法,於室溫下在鹽水溶液中浸濾該等試樣,並使其接觸大腸桿菌及金黃色葡萄球菌。浸濾至少一週後,並未發現細菌生長或細菌群集。
實例23-
藉使用Murine L 929纖維組織母細胞而測試根據實例15而塗覆之試樣的細胞毒害性效果。將該經塗覆試樣浸泡在培養基內,費時24小時,然後移除。在該培養基內之細胞殘存,然而,在濾出型殺生物劑之對照物內,該等細胞顯示幾乎100%壞血。
實例24-
使聚胺基甲酸乙酯薄膜經實例15之配方塗覆並測試其抗凝固作用。使用未經塗覆之試樣及實例3之經塗覆試樣作為對照物。藉添加氯化鈣(0.02M)而再活化新的檸檬酸化人類全血。將50微升再活化人血滴在面向上之經塗覆及非經塗覆聚胺基甲酸乙酯上。將該等經塗覆及未經塗覆聚胺基甲酸乙酯試樣以面朝上之方式放在具有約30°角之10厘米斜面上。將一滴再活化人血滴在該斜面之各頂部份上。在該未經塗覆之對照物上,以及在具有標準潤滑性塗料之試樣上,該血滴並未向下移動,而是藉停留在其滴下之位置而顯示形成凝固。置於根據本發明塗覆之該抗微生物試樣上之血滴因重力而向下移動。其在10分鐘內持續下向流動抵達該試樣之底部。結果顯示當在聚胺基甲酸乙酯基片上塗覆並固化時,該非濾出型抗微生物聚合物塗料並不會在該塗覆之基上形成血液凝固。
因此,雖然目前咸信已揭示本發明之較佳實施例,但是熟悉本項技藝者可瞭解只要不違背本發明之範圍或精神,可以有其它及進一步改變及修飾。
Claims (23)
- 一種可固化抗微生物塗料組成物,其包含:(a)以該組成物之重量為基準計,含量自約0.01%至約20%之至少一種聚胺基甲酸乙酯預聚物;其中該聚胺基甲酸乙酯預聚物包含一聚胺基甲酸乙酯主鏈,該主鏈包含至少一選自於下列基團所組成之群組之官能基:反應性異氰酸根、嵌段異氰酸根、硫異氰酸根、羧基、胺基、乙烯基及/或其等之組合,其中,在乾燥或固化該塗料組成物時,該官能基能夠直接地或是透過交聯劑與以下所界定的L之官能基形成化學鍵;(b)以該組成物之重量為基準計,含量自約99.89%至約75%之至少一種可至少部份溶解該聚胺基甲酸乙酯預聚物之載體溶劑;(c)以該組成物之重量為基準計,含量自0.01至約40%之一種親水性組份,其包含衍生自以下之親水性有機單體、寡聚物、預聚物、聚合物或共聚物:乙烯醇、N-乙烯基吡咯啶酮、N-乙烯基內醯胺、丙烯醯胺、醯胺、苯磺酸、乙烯基丁醛與N-乙烯基吡咯啶酮之組合、甲基丙烯酸羥乙酯、丙烯酸、乙烯基甲醚、乙烯基吡啶鎓鹵化物、甲基纖維素、乙基纖維素、羧甲基纖維素、羥乙基纖維素、羥丙基纖維素、羥甲基乙基纖維素、羥丙基甲基纖維素、乙酸纖維素、硝酸纖維素、澱粉、明膠、白蛋白、酪蛋白、樹膠、藻酸鹽、(甲基)丙烯酸羥乙酯、(甲基)丙烯酸羥丙酯、乙二醇(甲基)丙烯酸酯(例如三乙 二醇(甲基)丙烯酸酯及(甲基)丙烯醯胺)、N-烷基(甲基)丙烯醯胺(例如N-甲基(甲基)丙烯醯胺及N-己基(甲基)丙烯醯胺)、N-N-二烷基(甲基)丙烯醯胺(例如N,N-二甲基(甲基)丙烯醯胺及聚-N,N-二丙基(甲基)丙烯醯胺)、N-羥烷基(甲基)丙烯醯胺聚合物(諸如聚-N-羥甲基(甲基)丙烯醯胺及聚-N-羥乙基(甲基)丙烯醯胺),及N,N-二羥烷(甲基)丙烯醯胺聚合物(諸如聚-N,N-二羥乙基(甲基)丙烯醯胺)、醚多元醇、聚氧化乙烯、聚氧化丙烯,及聚(乙烯醚)、烷基乙烯基碸、烷基乙烯基碸-丙烯酸酯或其等之組合;及(d)以該組成物之重量為基準計,含量自約0.01%至約5%之至少一種四級銨化合物,且其具有下式:
其中:L代表烴基,其包含至少一種一旦藉蒸發該載體溶劑而固化該塗料組成物時可以與該聚胺基甲酸乙酯預聚物形成化學鍵之官能基,且其係自該固化塗料組成物之表面突出至少約15埃,藉以使該至少一種四級銨化合物穿過並超越隨著時間而沉積在該固化塗料組成物表面上之有機碎屑,其中在蒸發該載體溶劑時,該官能基可以直接或藉可交聯該四級銨化合物與聚胺基甲酸乙酯預聚物之交聯劑而與該聚胺基甲酸乙酯預聚物反 應;且R1 、R2 及R3 中至少一種代表可穿透微生物之細胞壁並殺滅該微生物之烴基。 - 如申請專利範圍第1項之塗料組成物,其進一步包含一改質聚合物,該改質聚合物係選自於下列所組成之群組:聚酯、聚醇酸、順丁烯二酸酐聚合物、順丁烯二酸酐共聚物、多元醇、聚胺、聚醯胺、聚丙烯酸酯、聚乙烯醇、聚乙酸乙烯、聚葡萄糖醯胺、聚葡萄糖胺、聚乙烯基吡咯啶酮、其等之共聚物及組合。
- 如申請專利範圍第1項之塗料組成物,其中以取代該載體溶劑之組成物重量為基準計,該親水聚合物、共聚物或預聚物係以自約0.2%至約15%之含量存在。
- 如申請專利範圍第3項之塗料組成物,其中該親水聚合物、共聚物或預聚物為N-聚乙烯基吡咯啶酮。
- 如申請專利範圍第1項之塗料組成物,其進一步包含一交聯劑,該交聯劑係選自於下列所組成之群組:吖丙啶、碳化二醯亞胺、蜜胺、多官能性醇、多官能性醛、多官能性胺、多官能性異氰酸酯及其等之組合。
- 如申請專利範圍第5項之塗料組成物,其中以取代該載體溶劑之組成物重量為基準計,該交聯劑係以自約0.001%至約5%之含量存在。
- 如申請專利範圍第1項之塗料組成物,其進一步包含反應增強觸媒。
- 如申請專利範圍第7項之塗料組成物,其中該觸媒係選 自由錫有機化合物、鈷有機化合物、三乙胺及其等之組合所組成之群組。
- 如申請專利範圍第1項之塗料組成物,其中該載體溶劑係選自於下列所組成之群組:水、甲基乙基酮、N-甲基吡咯啶酮、四氫呋喃、二氯甲烷、氯仿、乙酸乙酯、丙二醇甲基醚、丙二醇甲基醚乙酸酯、二丙酮醇、醚、酯、芳香烴、氯化烴、直鏈烴及其等之組合。
- 如申請專利範圍第1項之塗料組成物,其中當使用時,L之長度足以使相當量之帶正電荷的氮原子維持在累積於該固化組成物表面上之任何死微生物或碎屑上。
- 如申請專利範圍第1項之塗料組成物,其中該至少一種四級銨化合物係選自於下列物質所組成之群組:烷基羥乙基二甲基氯化銨、聚四級銨11、乙烯基吡咯啶酮與二甲胺基乙基甲基丙烯酸酯之季鹼化共聚物、聚四級銨16、聚四級銨44、乙烯基吡咯啶酮與季鹼化乙烯基咪唑之組合、聚四級銨55、乙烯基吡咯啶酮與二甲胺基乙基之季鹼化共聚物、N,N-二甲基-N-十二基-N-(2-羥基-3-磺丙基)銨甜菜鹼、N-烷基酸醯胺基丙基-N,N-二甲基-N-(3-磺丙基)-銨甜菜鹼、具長鏈烷基之3-氯-2-羥丙基-烷基-二甲基氯化銨,及其等之組合。
- 如申請專利範圍第1項之塗料組成物,其進一步包含一種欲自該固化塗料組成物濾出或欲與一交聯劑結合之額外組份,該交聯劑係選自於下列所組成之群組:抗微生物化合物、殺生物劑、抗生素、藥物、維生素、殺真 菌劑、制真菌劑、殺病毒劑、滅菌劑、殺精子劑、治療劑、肝素、植物萃取物及其等之組合。
- 一種可固化塗料組成物,其包含:含至少一種聚胺基甲酸乙酯預聚物之聚合物基質;其中該聚胺基甲酸乙酯預聚物包含一聚胺基甲酸乙酯主鏈,該主鏈包含至少一選自於下列基團所組成之群組之官能基:反應性異氰酸根、嵌段異氰酸根、硫異氰酸根、羧基、胺基、乙烯基及/或其等之組合,其中,在乾燥或固化該塗料組成物時,該官能基能夠直接地或是透過交聯劑與以下所界定的長鏈陽離子表面活化劑之官能基形成化學鍵;載體溶劑;至少一種長鏈陽離子表面活化劑化合物,其包含一種一旦蒸發該載體溶劑並乾燥或固化該組成物時,可以與該聚胺基甲酸乙酯預聚物形成化學鍵之官能基,該官能基係選自由胺、硫醇、羧基、醛、羥基及其等之組合所組成之群組;及至少一種衍生自以下之親水性有機單體、寡聚物、預聚物、聚合物或共聚物:乙烯醇、N-乙烯基吡咯啶酮、N-乙烯基內醯胺、丙烯醯胺、醯胺、苯磺酸、乙烯基丁醛與N-乙烯基吡咯啶酮之組合、甲基丙烯酸羥乙酯、丙烯酸、乙烯基甲醚、乙烯基吡啶鎓鹵化物、甲基纖維素、乙基纖維素、羧甲基纖維素、羥乙基纖維素、羥丙基纖維素、羥甲基乙基纖維素、羥丙基甲基纖維素、乙酸纖 維素、硝酸纖維素、澱粉、明膠、白蛋白、酪蛋白、樹膠、藻酸鹽、(甲基)丙烯酸羥乙酯、(甲基)丙烯酸羥丙酯、乙二醇(甲基)丙烯酸酯(例如三乙二醇(甲基)丙烯酸酯及(甲基)丙烯醯胺)、N-烷基(甲基)丙烯醯胺(例如N-甲基(甲基)丙烯醯胺及N-己基(甲基)丙烯醯胺)、N-N-二烷基(甲基)丙烯醯胺(例如N,N-二甲基(甲基)丙烯醯胺及聚-N,N-二丙基(甲基)丙烯醯胺)、N-羥烷基(甲基)丙烯醯胺聚合物(諸如聚-N-羥甲基(甲基)丙烯醯胺及聚-N-羥乙基(甲基)丙烯醯胺),及N,N-二羥烷(甲基)丙烯醯胺聚合物(諸如聚-N,N-二羥乙基(甲基)丙烯醯胺)、醚多元醇、聚氧化乙烯、聚氧化丙烯,及聚(乙烯醚)、烷基乙烯基碸、烷基乙烯基碸-丙烯酸酯或其等之組合,其中一旦乾燥或固化該組成物時,該長鏈陽離子表面活化劑化合物具非濾出性且係自該固化塗料組成物之表面突出至少約15埃藉以穿過並超越隨著時間沉積在該固化組成物之表面上的有機碎屑;且其中與不具有該至少一種長鏈陽離子表面活化劑化合物之類似塗料比較,該固化組成物顯示與該固化塗料接觸之血液減少的血液凝固。
- 如申請專利範圍第13項之可固化塗料組成物,其中該至少一種聚胺基甲酸乙酯預聚物含有至少一種一旦乾燥或固化該塗料組成物時可直接或經由交聯劑而與該長鏈化合物之官能基形成共價鍵之官能基。
- 如申請專利範圍第13項之可固化塗料組成物,其中該陽 離子表面活化劑為四級銨化合物。
- 如申請專利範圍第15項之可固化塗料組成物,其中該四級銨化合物係選自以下所組成之群組:烷基羥乙基二甲基氯化銨、聚四級銨11、乙烯基吡咯啶酮與二甲胺基乙基甲基丙烯酸酯之季鹼化共聚物、聚四級銨16、聚四級銨44、乙烯基吡咯啶酮與季鹼化乙烯基咪唑之組合、聚四級銨55、乙烯基吡咯啶酮與二甲胺基乙基之季鹼化共聚物、N,N-二甲基-N-十二基-N-(2-羥基-3-磺丙基)銨甜菜鹼、N-烷基酸醯胺基丙基-N,N-二甲基-N-(3-磺丙基)-銨甜菜鹼、具長鏈烷基之3-氯-2-羥丙基-烷基-二甲基氯化銨,及其等之組合。
- 如申請專利範圍第13項之可固化塗料組成物,其中該表面活化劑係自該固化塗層之表面突出至少約30埃。
- 如申請專利範圍第17項之可固化塗料組成物,其中該表面活化劑係自該固化塗層之表面突出至少約60埃。
- 如申請專利範圍第13項之可固化塗料組成物,其中該有機碎屑係選自由死微生物細胞、蛋白質狀積聚物及其等之組合所組成之群組。
- 如申請專利範圍第13項之可固化塗料組成物,其中與該未經塗覆之表面比較,當各經水或水性溶液濕潤時,該至少一種親水性水可溶有機單體、寡聚物、預聚物、聚合物或共聚物之含量足以使該固化組成物之摩擦力減少約70%。
- 如申請專利範圍第20項之可固化塗料組成物,其中該摩 擦力減少至少約80%。
- 如申請專利範圍第21項之可固化塗料組成物,其中該摩擦力減少至少約90%。
- 如申請專利範圍第22項之可固化塗料組成物,其中該摩擦力減少至少約95%。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/334,049 US20070166344A1 (en) | 2006-01-18 | 2006-01-18 | Non-leaching surface-active film compositions for microbial adhesion prevention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200738133A TW200738133A (en) | 2007-10-16 |
| TWI405536B true TWI405536B (zh) | 2013-08-21 |
Family
ID=38263429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096101746A TWI405536B (zh) | 2006-01-18 | 2007-01-17 | 用於防止微生物附著之非濾出型界面活性膜組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070166344A1 (zh) |
| EP (1) | EP1984121B1 (zh) |
| JP (1) | JP2009523890A (zh) |
| KR (1) | KR20080110578A (zh) |
| CN (1) | CN101374607A (zh) |
| AU (1) | AU2007207708B2 (zh) |
| BR (1) | BRPI0706622A2 (zh) |
| CA (1) | CA2636975C (zh) |
| IL (1) | IL192817A0 (zh) |
| MX (1) | MX355848B (zh) |
| NO (1) | NO20083155L (zh) |
| TW (1) | TWI405536B (zh) |
| WO (1) | WO2007084452A2 (zh) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080114096A1 (en) * | 2006-11-09 | 2008-05-15 | Hydromer, Inc. | Lubricious biopolymeric network compositions and methods of making same |
| CN101896541B (zh) * | 2007-10-31 | 2014-05-07 | 杜邦泰吉恩胶卷美国有限公司 | 涂布的制品 |
| JP2011503332A (ja) * | 2007-11-19 | 2011-01-27 | ユニヴァーシティ オブ ワシントン | 船舶コーティング |
| US9533006B2 (en) | 2007-11-19 | 2017-01-03 | University Of Washington | Marine coatings |
| US10092881B2 (en) | 2008-01-25 | 2018-10-09 | Bha Altair, Llc | Permanent hydrophilic porous coatings and methods of making them |
| US9139355B2 (en) * | 2008-04-18 | 2015-09-22 | Medline Industries, Inc. | Glove packaging having antimicrobial barrier |
| EP2309851A2 (en) * | 2008-05-29 | 2011-04-20 | DSM IP Assets B.V. | Antimicrobial polymers and their uses |
| US9072292B2 (en) * | 2008-06-06 | 2015-07-07 | T. Brian Cavitt | Biofilm resistant polymer materials |
| WO2010021920A1 (en) * | 2008-08-20 | 2010-02-25 | Rhein Chemie Corporation | Polyol compositions |
| EP2161311B1 (en) * | 2008-09-04 | 2011-06-29 | Rohm and Haas Company | Microbiocidal coatings |
| US20120135658A1 (en) * | 2008-09-30 | 2012-05-31 | General Electric Company | Protective article and methods of manufacture thereof |
| US20100135949A1 (en) * | 2008-12-01 | 2010-06-03 | Becton, Dickinson And Company | Antimicrobial compositions |
| DE102009014699A1 (de) * | 2009-03-27 | 2010-10-07 | Carl Freudenberg Kg | Verfahren zur Herstellung einer reaktiven Polyurethan-Emulsion |
| EP2270087A1 (de) * | 2009-06-30 | 2011-01-05 | LANXESS Deutschland GmbH | Heterocyclische 3-Ringverbindungen und jodhaltige Verbindungen enthaltende Polymere |
| US8821455B2 (en) | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
| US20110076332A1 (en) * | 2009-08-27 | 2011-03-31 | Xiaojun Yu | Dextran-chitosan based in-situ gelling hydrogels for biomedical applications |
| US20110117352A1 (en) * | 2009-10-28 | 2011-05-19 | Shalaby Shalaby W | Self-primed fabric in self-reinforced polyethylene composites |
| US20110160333A1 (en) * | 2009-12-31 | 2011-06-30 | Hillcrest Financial Partners, LLC | Antimicrobial surface and surface coats |
| CN102329548B (zh) | 2010-07-13 | 2014-12-31 | 罗门哈斯公司 | 杀微生物涂料 |
| JP5601115B2 (ja) * | 2010-09-17 | 2014-10-08 | デクセリアルズ株式会社 | 潜在性硬化剤の製造方法 |
| BR112013009784A2 (pt) | 2010-10-22 | 2016-07-19 | Univ City New York Res Found | método para conferir atividade microbicida a um substrato |
| US9353646B2 (en) | 2011-01-19 | 2016-05-31 | President And Fellows Of Harvard College | Slippery surfaces with high pressure stability, optical transparency, and self-healing characteristics |
| CA2825012C (en) | 2011-01-19 | 2021-03-23 | President And Fellows Of Harvard College | Slippery liquid-infused porous surfaces and biological applications thereof |
| GB201107183D0 (en) * | 2011-04-28 | 2011-06-15 | Gx Labs Holdings Ltd | Biocide-coated substrate |
| US10653133B2 (en) * | 2011-05-10 | 2020-05-19 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
| AU2015261645B2 (en) * | 2011-05-10 | 2017-10-19 | Osartis Gmbh | Antimicrobial solid and methods of making and using same |
| BR112013033475A2 (pt) | 2011-06-28 | 2017-12-19 | Ctc Bio Inc | composição farmacêutica para tratamento, prevenção ou melhora da ejaculação precoce e método para tratamento, prevenção ou melhora da ejaculação precoce |
| BR112013032821A2 (pt) | 2011-07-06 | 2017-01-31 | Nbc Meshtec Inc | membro de resina antiviral e método para a produção do mesmo |
| US9511147B2 (en) | 2011-08-12 | 2016-12-06 | Rutgers, The State University Of New Jersey | Interpolymer network delivery system |
| KR20140111338A (ko) * | 2012-01-10 | 2014-09-18 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 유체 및 고체 반발성을 위한 표면들의 개질 |
| US9352119B2 (en) | 2012-05-15 | 2016-05-31 | Becton, Dickinson And Company | Blood control IV catheter with antimicrobial properties |
| CA2878683C (en) | 2012-07-12 | 2021-07-20 | President And Fellows Of Harvard College | Slippery self-lubricating polymer surfaces |
| WO2014012052A1 (en) | 2012-07-13 | 2014-01-16 | President And Fellows Of Harvard College | Slips surface based on metal-containing compound |
| US9630224B2 (en) | 2012-07-13 | 2017-04-25 | President And Fellows Of Harvard College | Slippery liquid-infused porous surfaces having improved stability |
| EP3327090A1 (en) * | 2012-07-18 | 2018-05-30 | President and Fellows of Harvard College | Modification of surfaces for simulataneous repellency and targeted binding of desired moieties |
| US9579486B2 (en) | 2012-08-22 | 2017-02-28 | Becton, Dickinson And Company | Blood control IV catheter with antimicrobial properties |
| JP2014097479A (ja) * | 2012-11-15 | 2014-05-29 | Nagase & Co Ltd | 静電噴霧液調製用溶媒、静電噴霧液、及び、静電噴霧方法 |
| JP6043737B2 (ja) * | 2013-01-30 | 2016-12-14 | 富士フイルム株式会社 | 放射線撮影装置 |
| US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
| US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
| US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
| US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
| EP2969258A4 (en) | 2013-03-13 | 2016-11-30 | Harvard College | COMPRESSIVE COMPOSITION FOR PREPARING GLOSSY SURFACES WITH LIQUID INFUSION AND METHOD OF USE |
| JP6100893B2 (ja) * | 2013-05-27 | 2017-03-22 | Jsr株式会社 | 無機材料で構成される表面用の表面処理剤、表面が改質された器具および装置、該器具および装置の製造方法 |
| CA2952867C (en) * | 2013-06-18 | 2022-05-03 | Chemgreen Innovation Inc. | An antimicrobial polymer wherein an aromatic moiety is covalently incorporated into the polymer backbone through loss of aromaticity |
| US10245355B2 (en) | 2013-07-10 | 2019-04-02 | President And Fellows Of Harvard College | Modification of surfaces for fluid and solid repellency |
| CN103416398A (zh) * | 2013-07-26 | 2013-12-04 | 广州联庄科技有限公司 | 一种光固化抗菌剂及其固化方法及应用 |
| AU2014363936B2 (en) * | 2013-12-12 | 2018-07-26 | Hollister Incorporated | Water disintegrable flushable catheter with a hydrophilic coating |
| US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
| US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
| US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
| US20150342990A1 (en) * | 2014-05-29 | 2015-12-03 | Metabeauty, Inc | Methods and compositions for the use of silver to prevent and treat acne |
| KR101652263B1 (ko) | 2014-06-13 | 2016-08-30 | (주)콜로디스 바이오사이언스 | 항균 펩티드를 포함하는 접착 단백질 및 이를 포함하는 항균 코팅 조성물 |
| US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
| CN104387832B (zh) * | 2014-09-29 | 2016-06-08 | 北京师范大学 | 一种负载有小分子物质的复合抑菌涂层制备方法 |
| US20160114958A1 (en) * | 2014-10-24 | 2016-04-28 | David A. Busche | Chemotaxis Antibacterial Film and Package |
| CA3054502A1 (en) * | 2015-02-27 | 2016-09-01 | Livinguard Ag | Textiles having antimicrobial properties |
| CN107635589B (zh) * | 2015-03-06 | 2020-07-17 | 约翰·保罗·威尔逊 | 本质上抗微生物剂多孔基质复合物和制造其的方法 |
| KR102424889B1 (ko) | 2015-06-08 | 2022-07-25 | 콜로디스 바이오사이언스, 인코포레이티드 | 생리기능성 접착제 조성물 |
| EP3337324B1 (en) | 2015-07-27 | 2020-06-03 | Kimberly-Clark Worldwide, Inc. | Residual disinfectant composition |
| US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
| GB201520751D0 (en) * | 2015-11-24 | 2016-01-06 | Biointeractions Ltd | Coatings for medical devices |
| EP3481197B1 (en) * | 2016-07-08 | 2022-09-21 | Bemis Company, Inc. | Antimicrobial packaging films |
| WO2018013805A2 (en) | 2016-07-14 | 2018-01-18 | Hollister Incorporated | Hygienic medical devices having hydrophilic coating and methods of forming the same |
| WO2018124303A1 (ja) * | 2016-12-29 | 2018-07-05 | アルケア株式会社 | 発泡体及び発泡体用組成物 |
| US11369109B2 (en) * | 2020-06-11 | 2022-06-28 | Hrl Laboratories, Llc | Fast-acting antimicrobial surfaces, and methods of making and using the same |
| KR102190865B1 (ko) | 2017-10-23 | 2020-12-14 | 주식회사 엘지화학 | 항균성 고분자 코팅 조성물 및 항균성 고분자 필름 |
| US10967082B2 (en) | 2017-11-08 | 2021-04-06 | Parasol Medical, Llc | Method of limiting the spread of norovirus within a cruise ship |
| WO2019136401A1 (en) * | 2018-01-05 | 2019-07-11 | Freeflow Medical Devices Llc | Extracorporeal membrane oxygenation apparatuses and methods of their preparation and use |
| US20210077668A1 (en) * | 2018-01-05 | 2021-03-18 | Clemson University Research Foundation | Highly Adherent Polymers for Orthopedic Device Coatings |
| JP2019119725A (ja) | 2018-01-11 | 2019-07-22 | スリーエム イノベイティブ プロパティズ カンパニー | 撥菌性組成物、撥菌性コーティング及びその形成方法、並びに撥菌性コーティングを有する物品 |
| CN108245222A (zh) * | 2018-01-23 | 2018-07-06 | 青岛星创医疗科技有限公司 | 医用取石球囊的制备方法 |
| US20190230929A1 (en) * | 2018-01-30 | 2019-08-01 | W.M. Barr & Company, Inc. | Composition for residual sanitization |
| JP7128632B2 (ja) * | 2018-02-26 | 2022-08-31 | 株式会社日本触媒 | 医療用具用コーティング剤、医療用具用硬化性コーティング剤、医療用具用重合体、コーティング方法、医療用具及びその製造方法 |
| US10864058B2 (en) | 2018-03-28 | 2020-12-15 | Parasol Medical, Llc | Antimicrobial treatment for a surgical headlamp system |
| EP3802122B1 (en) | 2018-05-25 | 2023-08-16 | Cryovac, LLC | Method of making an antimicrobial multilayer film |
| CN110655815B (zh) * | 2018-06-29 | 2022-01-25 | 3M创新有限公司 | 具有长期抗菌性能的涂料组合物 |
| US20200071540A1 (en) * | 2018-09-04 | 2020-03-05 | Parasol Medical LLC | Antimicrobial coating applied to protective body equipment such as helmets, shoulder pads, and elbow pads |
| CN109010897B (zh) * | 2018-09-08 | 2020-11-27 | 珠海市雅莎医疗器械有限公司 | 一种医用抗菌凝胶敷料的制备方法 |
| WO2020077161A1 (en) | 2018-10-11 | 2020-04-16 | Freeflow Medical Devices Llc | Packaging for medical devices coated with perfluorinated liquids or dispersions thereof |
| WO2020077160A1 (en) | 2018-10-11 | 2020-04-16 | Freeflow Medical Devices Llc | Fluoropolymer based anti-thrombotic coatings |
| CN113164641B (zh) * | 2018-12-12 | 2022-12-30 | 东丽株式会社 | 医疗设备和其制造方法 |
| CN113784843B (zh) * | 2019-04-25 | 2024-03-26 | 株式会社可乐丽 | 涂覆组合物以及使用其的防雾性构件、防污性构件、层叠体和抗菌制品 |
| CN111004493B (zh) * | 2019-12-24 | 2021-09-10 | 宁波蓝柏医疗器械有限公司 | 抗菌医用材料及其制备方法 |
| US20210299309A1 (en) * | 2020-03-31 | 2021-09-30 | Parasol Medical, Llc | Tent with antimicrobial treatment applied thereto and method of imparting antimicrobial properties to the tent |
| US20230210108A1 (en) * | 2020-05-27 | 2023-07-06 | Vacopak Industries Ltd. | Antimicrobial coating for polymeric food packaging |
| ES2776573B2 (es) * | 2020-06-19 | 2021-01-04 | Drylyte Sl | Recubrimiento auto desinfectante para superficies |
| EP4552661A3 (en) * | 2020-07-13 | 2025-07-23 | Hollister Incorporated | Medical devices having anti-microbial properties and methods for making the same |
| US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
| KR20230074799A (ko) | 2020-10-01 | 2023-05-31 | 이뮤니컴 인코포레이티드 | 리간드의 침출 감소 |
| US12364265B2 (en) * | 2020-10-06 | 2025-07-22 | Carefusion 2200, Inc. | Inclusion of bound antiseptic in a luer lock |
| CN113712028A (zh) * | 2020-10-21 | 2021-11-30 | 南京百思福医药科技有限公司 | 一种光致发光长效成膜消毒组合物及其制备方法与应用 |
| CN112279994B (zh) * | 2020-11-06 | 2022-08-16 | 江苏海洋大学 | 一种聚氨酯基互穿网络聚合物在医用导管表面改性中的应用 |
| CN112250901B (zh) * | 2020-11-06 | 2022-04-01 | 江苏海洋大学 | 一种多功能互穿网络聚合物乳液在聚氨酯软泡塑料改性中的应用 |
| CN113398314A (zh) * | 2021-06-11 | 2021-09-17 | 长春工业大学 | 一种手持静电纺丝单向导液伤口敷料的制备方法 |
| CN113502101A (zh) * | 2021-07-31 | 2021-10-15 | 百草边大生物科技(青岛)有限公司 | 一种大生物水性漆的制备方法 |
| CN115814156B (zh) * | 2021-09-16 | 2024-01-26 | 齐鲁工业大学 | 一种用于人工器官的耐腐蚀抗菌涂层及其制备方法 |
| WO2023075664A1 (en) * | 2021-10-26 | 2023-05-04 | Rise Research Institutes of Sweden AB | A disinfectant film-forming composition and a dry disinfectant film formed on a surface from the film forming composition |
| KR20230080662A (ko) | 2021-11-30 | 2023-06-07 | (주) 씨에프씨테라메이트 | 태양열 차단 성능이 향상된 농원예용 필름 조성물 및 이의 제조방법 |
| US20250051547A1 (en) * | 2022-01-28 | 2025-02-13 | Nano And Advanced Materials Institute Limited | Antimicrobial compositions with enhanced efficacy and prolonged performance lifetime, and preparation method thereof |
| CN114716719B (zh) * | 2022-03-10 | 2023-09-01 | 大连理工大学 | 一种使用聚合物链在水溶液中对聚酯材料进行表面修饰的方法 |
| GB202205496D0 (en) * | 2022-04-13 | 2022-05-25 | Univ Bristol | Antimicrobial porous frameworks |
| CN114849501B (zh) * | 2022-05-30 | 2023-05-26 | 沃顿科技股份有限公司 | 纳滤膜的制备方法及由其制备的纳滤膜 |
| CN115920141B (zh) * | 2022-12-12 | 2024-03-19 | 广东省人民医院 | 一种抗菌抗微生物黏附引流管及其制备方法 |
| CN116478439B (zh) * | 2023-05-04 | 2025-02-07 | 江苏海洋大学 | 一种功能型异氰酸酯交联剂在聚氯乙烯材料表面改性中的应用 |
| CH720895A2 (de) * | 2023-06-27 | 2025-01-15 | Fasano Simon | Papierklammer |
| CN116948157B (zh) * | 2023-07-25 | 2025-09-30 | 擎天材料科技有限公司 | 一种低温固化高流平聚酯树脂及其制备方法和应用 |
| CN117402683A (zh) * | 2023-10-20 | 2024-01-16 | 北京白象新技术有限公司 | 一种邻苯灰染去污膏及其制备方法和应用 |
| KR102844759B1 (ko) * | 2025-01-10 | 2025-08-08 | 김지웅 | 항균 펩티드가 포함된 항균 필름, 이의 제조방법 및 이것을 포함하는 식품 포장지 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642267A (en) * | 1985-05-06 | 1987-02-10 | Hydromer, Inc. | Hydrophilic polymer blend |
| WO2002010244A2 (en) * | 2000-07-27 | 2002-02-07 | 3M Innovative Properties Company | Biocidal polyurethane compositions and method of use |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US227101A (en) * | 1880-05-04 | Music-recording attachment for keyed instruments | ||
| US2510428A (en) * | 1948-05-18 | 1950-06-06 | Goodrich Co B F | Bactericidal and bacteriostatic preparations comprising 2, 3-diaryl indoles |
| GB871228A (en) | 1959-09-09 | 1961-06-21 | Steril Plast Inc | Bacteriostatic plastic |
| JPS5413694A (en) * | 1977-07-01 | 1979-02-01 | Sumitomo Electric Industries | Composite blood vessel prosthesis and method of producing same |
| US4167823A (en) * | 1978-06-21 | 1979-09-18 | Kumming Deborah G | Coagulation puzzle for teaching coagulation theory |
| US4217254A (en) * | 1978-12-20 | 1980-08-12 | Synthetic Surfaces, Inc. | High green strength curable urethane adhesive |
| JPS57134419A (en) * | 1981-02-12 | 1982-08-19 | Eisai Co Ltd | Stable anticoagulant of blood |
| ATE17262T1 (de) * | 1981-11-02 | 1986-01-15 | Pentapharm Ag | Verfahren zur quantitativen bestimmung von blutgerinnungsfaktor xii in humanplasma. |
| US4467073A (en) * | 1982-10-20 | 1984-08-21 | Hydromer, Inc. | Transparent anti-fog coating compositions |
| US4613517A (en) * | 1983-04-27 | 1986-09-23 | Becton, Dickinson And Company | Heparinization of plasma treated surfaces |
| US4631297A (en) * | 1984-03-12 | 1986-12-23 | Dow Corning Corporation | Antimicrobially effective organic foams and methods for their preparation |
| US4554862A (en) * | 1984-06-21 | 1985-11-26 | Air Vent Inc. | Roof ridge ventilator for retarding microbe growth in shingle roofs |
| DE8432064U1 (de) * | 1984-11-02 | 1985-05-02 | Codan Medizinische Geräte GmbH & Co KG, 2432 Lensahn | Vorrichtung zur regulierung des durchflusses bei der schwerkraft-infusion und -transfusion |
| US4678660A (en) * | 1984-12-07 | 1987-07-07 | Deseret Medical, Inc. | Thermoplastic polyurethane anticoagulant alloy coating |
| US5998200A (en) * | 1985-06-14 | 1999-12-07 | Duke University | Anti-fouling methods using enzyme coatings |
| US4713402A (en) * | 1985-08-30 | 1987-12-15 | Becton, Dickinson And Company | Process for preparing antithrombogenic/antibiotic polymeric plastic materials |
| US5024875A (en) * | 1986-09-09 | 1991-06-18 | Burlington Industries, Inc. | Antimicrobial microporous coating |
| US4880883A (en) * | 1987-06-03 | 1989-11-14 | Wisconsin Alumni Research Foundation | Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate |
| US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
| US5165952A (en) * | 1989-01-18 | 1992-11-24 | Becton, Dickinson And Company | Anti-infective and antithrombogenic medical articles and method for their preparation |
| JP2727008B2 (ja) * | 1989-02-01 | 1998-03-11 | 日本酸素株式会社 | 静菌化水の製造方法 |
| CA1316623C (en) * | 1989-04-06 | 1993-04-20 | Pavel Stovicek | Biocidal surface coating and casting compositions based on quarternary ammonium salts of nalkyl x,x bis (4,4' hydroxyphenyl) and quarternary salts of polyglycols as backbones of resins |
| USRE38558E1 (en) * | 1991-03-19 | 2004-07-20 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US5175402A (en) | 1992-04-10 | 1992-12-29 | Olson Delwyn L | Mercury float switch |
| US5783502A (en) * | 1995-06-07 | 1998-07-21 | Bsi Corporation | Virus inactivating coatings |
| EP0952168A4 (en) * | 1996-07-16 | 2000-05-24 | Toray Industries | GRAFT POLYMERS AND THEIR USE IN MEDICAL APPARATUS |
| US6039940A (en) * | 1996-10-28 | 2000-03-21 | Ballard Medical Products | Inherently antimicrobial quaternary amine hydrogel wound dressings |
| FR2757866B1 (fr) * | 1996-12-30 | 2004-12-17 | Catalyse | Polymeres comportant des groupes ammoniums quaternaires, leur utilisation pour la fabrication d'un materiau a propretes antibacteriennes et leurs procedes de preparation |
| DE19709076A1 (de) * | 1997-03-06 | 1998-09-10 | Huels Chemische Werke Ag | Verfahren zur Herstellung antimikrobieller Kunststoffe |
| US5954869A (en) * | 1997-05-07 | 1999-09-21 | Bioshield Technologies, Inc. | Water-stabilized organosilane compounds and methods for using the same |
| US6113815A (en) * | 1997-07-18 | 2000-09-05 | Bioshield Technologies, Inc. | Ether-stabilized organosilane compositions and methods for using the same |
| US6054504A (en) | 1997-12-31 | 2000-04-25 | Hydromer, Inc. | Biostatic coatings for the reduction and prevention of bacterial adhesion |
| US6440442B1 (en) * | 1998-06-29 | 2002-08-27 | Hydromer, Inc. | Hydrophilic polymer blends used for dry cow therapy |
| US6395289B1 (en) * | 1998-06-29 | 2002-05-28 | Hydromer, Inc. | Hydrophilic polymer blends used to prevent cow skin infections |
| US6203812B1 (en) * | 1998-06-29 | 2001-03-20 | Hydromer, Inc. | Hydrophilic polymer blends used to prevent cow skin infections |
| US6224655B1 (en) * | 1998-11-03 | 2001-05-01 | Pierre Messier | Biostatic air filter |
| US6296863B1 (en) * | 1998-11-23 | 2001-10-02 | Agion Technologies, Llc | Antimicrobial fabric and medical graft of the fabric |
| US7709694B2 (en) * | 1998-12-08 | 2010-05-04 | Quick-Med Technologies, Inc. | Materials with covalently-bonded, nonleachable, polymeric antimicrobial surfaces |
| US6716895B1 (en) * | 1999-12-15 | 2004-04-06 | C.R. Bard, Inc. | Polymer compositions containing colloids of silver salts |
| US20020051754A1 (en) * | 2000-04-13 | 2002-05-02 | Schroeder Joseph D. | Anti-microbial packaging polymer and its method of use |
| US6599448B1 (en) * | 2000-05-10 | 2003-07-29 | Hydromer, Inc. | Radio-opaque polymeric compositions |
| US6379702B1 (en) * | 2000-07-05 | 2002-04-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| US6203317B1 (en) * | 2000-07-19 | 2001-03-20 | Tp Orthodontics, Inc. | Orthodontic elastomeric ligature with slippery coating and method of making same |
| DE10061250A1 (de) * | 2000-12-09 | 2002-06-13 | Creavis Tech & Innovation Gmbh | Verfahren zur thermisch unterstützten antimikrobiellen Oberflächenausrüstung |
| DE10062201A1 (de) * | 2000-12-13 | 2002-06-20 | Creavis Tech & Innovation Gmbh | Verfahren zum Einsatz antimikrobieller Polymere im Bauten- und Denkmalschutz |
| DE10102900A1 (de) * | 2001-01-23 | 2002-07-25 | Creavis Tech & Innovation Gmbh | Antimikrobielle Polymere in Reaktivformulierungen |
| DE10110885A1 (de) * | 2001-03-07 | 2002-09-12 | Creavis Tech & Innovation Gmbh | Mokrobizide Trennsysteme |
| WO2002085387A2 (en) * | 2001-04-23 | 2002-10-31 | Nucryst Pharmaceuticals Corp. | A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
| US7151139B2 (en) * | 2001-04-23 | 2006-12-19 | Massachusetts Institute Of Technology | Antimicrobial polymeric surfaces |
| US7402318B2 (en) * | 2001-11-14 | 2008-07-22 | Novartis Ag | Medical devices having antimicrobial coatings thereon |
| US7005031B2 (en) * | 2002-01-16 | 2006-02-28 | 3M Innovative Properties Company | Pressure sensitive adhesives having quaternary ammonium functionality, articles, and methods |
| FR2834992B1 (fr) | 2002-01-21 | 2005-05-27 | Oreal | Polymeres associatifs cationiques amphiphiles, procede de preparation, utilisation comme epaississant et composition les comprenant |
| US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
| US20040109853A1 (en) * | 2002-09-09 | 2004-06-10 | Reactive Surfaces, Ltd. | Biological active coating components, coatings, and coated surfaces |
| US20050095351A1 (en) * | 2003-05-29 | 2005-05-05 | Jona Zumeris | Method, apparatus and system for nanovibration coating and biofilm prevention associated with medical devices |
| DE10343730A1 (de) * | 2003-09-22 | 2005-04-21 | Clariant Gmbh | Hochkonzentrierte wässrige Lösung amphoterer Tenside |
| US20050191270A1 (en) * | 2004-02-27 | 2005-09-01 | Hydromer, Inc. | Anti-infectious hydrogel compositions |
| US20050249791A1 (en) * | 2004-05-07 | 2005-11-10 | 3M Innovative Properties Company | Antimicrobial articles |
-
2006
- 2006-01-18 US US11/334,049 patent/US20070166344A1/en not_active Abandoned
-
2007
- 2007-01-16 WO PCT/US2007/001026 patent/WO2007084452A2/en not_active Ceased
- 2007-01-16 EP EP07718288.9A patent/EP1984121B1/en active Active
- 2007-01-16 MX MX2008009326A patent/MX355848B/es active IP Right Grant
- 2007-01-16 CN CNA2007800032265A patent/CN101374607A/zh active Pending
- 2007-01-16 KR KR1020087019541A patent/KR20080110578A/ko not_active Ceased
- 2007-01-16 CA CA2636975A patent/CA2636975C/en not_active Expired - Fee Related
- 2007-01-16 JP JP2008551311A patent/JP2009523890A/ja active Pending
- 2007-01-16 BR BRPI0706622-8A patent/BRPI0706622A2/pt not_active Application Discontinuation
- 2007-01-16 AU AU2007207708A patent/AU2007207708B2/en not_active Ceased
- 2007-01-17 TW TW096101746A patent/TWI405536B/zh not_active IP Right Cessation
-
2008
- 2008-07-15 IL IL192817A patent/IL192817A0/en unknown
- 2008-07-17 NO NO20083155A patent/NO20083155L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642267A (en) * | 1985-05-06 | 1987-02-10 | Hydromer, Inc. | Hydrophilic polymer blend |
| WO2002010244A2 (en) * | 2000-07-27 | 2002-02-07 | 3M Innovative Properties Company | Biocidal polyurethane compositions and method of use |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20083155L (no) | 2008-09-29 |
| MX2008009326A (es) | 2008-09-29 |
| IL192817A0 (en) | 2009-02-11 |
| US20070166344A1 (en) | 2007-07-19 |
| CA2636975C (en) | 2015-07-07 |
| WO2007084452A2 (en) | 2007-07-26 |
| BRPI0706622A2 (pt) | 2011-04-05 |
| CN101374607A (zh) | 2009-02-25 |
| TW200738133A (en) | 2007-10-16 |
| CA2636975A1 (en) | 2007-07-26 |
| AU2007207708B2 (en) | 2013-07-18 |
| EP1984121A4 (en) | 2012-02-22 |
| EP1984121A2 (en) | 2008-10-29 |
| KR20080110578A (ko) | 2008-12-18 |
| AU2007207708A1 (en) | 2007-07-26 |
| MX355848B (es) | 2018-04-26 |
| WO2007084452A3 (en) | 2007-12-21 |
| EP1984121B1 (en) | 2019-05-08 |
| JP2009523890A (ja) | 2009-06-25 |
| WO2007084452A8 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI405536B (zh) | 用於防止微生物附著之非濾出型界面活性膜組成物 | |
| Bai et al. | Antifogging/antibacterial coatings constructed by N-hydroxyethylacrylamide and quaternary ammonium-containing copolymers | |
| US20110200655A1 (en) | Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic | |
| EP2805734B1 (en) | Antimicrobial wound-covering material and method for manufacturing same | |
| JPH0790039B2 (ja) | 感染抵抗性組成物の製造方法 | |
| JP5323814B2 (ja) | 共有結合している抗生物質製剤を有するポリマー | |
| JPH02504151A (ja) | 殺生物剤投薬システムとその製造方法 | |
| PL218789B1 (pl) | Wodna kompozycja powłokowa | |
| CA2690880A1 (en) | Antimicrobial polyurethane resins and products made therefrom | |
| EP3694568B1 (en) | Amphiphilic antimicrobial hydrogel | |
| CA2777213A1 (en) | Antimicrobial composition | |
| AU2002233502A1 (en) | Methods and clinical devices for the inhibition or prevention of mammalian cell growth | |
| EP1408942A1 (en) | Methods and clinical devices for the inhibition or prevention of mammalian cell growth | |
| US9723843B2 (en) | Family of silver (I) periodate compounds having broad microbial properties | |
| US20060051402A1 (en) | Splinting orthopedic and rehabilitative product | |
| EP2968686A1 (en) | Polymeric coatings having antimicrobial properties | |
| KR100315334B1 (ko) | 키토산을이용한항균필터의제조법 | |
| US20160106879A1 (en) | Antiseptic wound dressing | |
| AU2013245551B2 (en) | Non-leaching surface-active film compositions for microbial adhesion prevention | |
| EP1912683B1 (en) | Antimicrobial composition | |
| AU2023436112A1 (en) | A method for imparting antimicrobial properties to a synthetic substrate | |
| Szycher | Polyurethanes: Antimicrobial | |
| Szycher | -Antimicrobial Polyurethanes | |
| WO2006028463A1 (en) | Splinting orthopedic and rehabilitative product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |